AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Research Library · Biotech & Healthcare

Biotech Stock Research Reports: Clinical Trials, FDA Catalysts and Cash

Dated PDF research reports on U.S.-listed biotechnology and healthcare companies. Each report follows one company through its lead programs and trial design, the regulatory path, cash, burn and runway, dilution, ownership and the catalyst map. Every report is a snapshot of the research on the date printed on its cover; the linked stock hub follows the current situation.

1 · AccessUnlock the library by watching a short ad or with a contribution.
2 · DownloadEach access includes up to 2 reports, valid for 12 hours.
3 · ReadEvery report carries its date, its sources and its disclaimer. Redistribution is prohibited.
Library access
Unlock the reports

Watch a short ad or support Merlintrader with a contribution. You decide, we don’t recommend.

OR

Subscribe free to the newsletter for a monthly pass that renews automatically while you stay subscribed.

Note: the “watch an ad” option is not available when an ad blocker or other ad-blocking tools are active. To use it, please allow ads on merlintrader.com; otherwise the Library can be opened with a contribution.

The newsletter: 1 to 3 emails a week with our latest stock hubs, research reports and key catalyst updates. Newsletter options unlock the library only after you confirm your email (check your inbox). Then: one-month pass, renewed automatically each month while you stay subscribed · 5 reports a day.

The library is open. Up to 2 downloads are included with this access.

Biotech and healthcare reports in the library

The reports cover clinical-stage and commercial companies in oncology and hematology, neurology and psychiatry, rare and genetic diseases, ophthalmology, immunology and inflammation, cardiometabolic disease, gene editing and RNA medicines, vaccines, diagnostics and medical technology. The newest reports come first. Unlock the library once with the button above, then choose up to two reports within the next 12 hours.

$DTILResearch updated November 6, 2026PDF · 15 pages

Precision BioSciences: PBGENE-HBV data, FUNCTION-DMD and the November offering

In vivo gene editing research: PBGENE-HBV Phase 1 data, the first FUNCTION-DMD participant, liquidity at September 30, the November equity offering and the AASLD presentation.

$ACRSResearch updated November 5, 2026PDF · 25 pages

Aclaris Therapeutics: Q3 Results, Bosakitug and ATI-052

Q3 results, the October equity financing, bosakitug, ATI-052 and the oral ITK pipeline.

$XENEResearch as of November 1, 2026PDF · 19 pages

XENE Stock Hub: Xenon Pharmaceuticals News, Azetukalner and Epilepsy

Xenon Pharmaceuticals stock news: $1.245 billion June liquidity, an azetukalner NDA, a psychiatry enrollment pause and pain studies ahead.

$TAKResearch as of November 1, 2026PDF · 20 pages

TAK Stock Hub: Takeda News, New Medicine Launches and Pipeline Catalysts

Takeda stock news: JPY 2.407tn H1 revenue, new launches, zasocitinib review, debt, ADS structure and the December strategy event.

$ZYMEArchive captured October 31, 2026PDF · 19 pages

Zymeworks: Ziihera economics, Theravance and the owned pipeline

This research separates Ziihera milestone and royalty economics from the Theravance acquisition and YUPELRI collaboration revenue. It examines acquisition financing, capital allocation, the HERIZON-GEA-01 evidence, ZW191 dose optimization and the October Roche license for ZW209, preserving the original reference dates. Original research revision date not stated; archive copy captured October 31, 2026.

$TRAWArchive captured October 31, 2026PDF · 17 pages

Traws Pharma: antiviral evidence, holds and funding

This archive traces tivoxavir and ratutrelvir through clinical evidence, regulatory setbacks and the limits of early antiviral results. It examines the financing triggers, warrants, Nasdaq requirements and legacy oncology assets that make permission to study, interpretable data and available capital interdependent. The original research revision date is not stated; this archive copy was captured on October 31, 2026.

$TARAResearch updated November 8, 2026PDF · 20 pages

Protara: TARA-002, IV Choline Chloride and development economics

Research covering the bladder-cancer and lymphatic-malformation evidence for TARA-002 and the separate replacement-biology rationale behind IV Choline Chloride. It examines THRIVE-3 enrollment, response denominators, regulatory and manufacturing tasks, the September 30, 2026 accounts and the November 4, 2026 manufacturing acquisition.

$PHVSArchive captured October 31, 2026PDF · 14 pages

Pharvaris: response endpoints, prevention evidence and separate filings

Archived research distinguishes RAPIDe-3 on-demand response times from CHAPTER-3 prevention endpoints and the acquired-angioedema CREAATE program. It examines safety, longer-term exposure, regulatory sequencing, commercial differentiation, euro cash consumption, equity financing and the gap between pivotal evidence and an approved business. Original research revision date not stated; archive copy captured October 31, 2026.

$LBRXArchive captured October 31, 2026PDF · 17 pages

LB Pharmaceuticals: NOVA evidence, tolerability and pivotal funding

Archived research examines LB-102 pharmacology, the randomized NOVA-1 dose comparisons and the limits of exploratory cognition findings. It separates measured weight changes from adverse-event summaries and follows NOVA-2, long-term safety development, June liquidity, July financing, employee equity and dilution. Original research revision date not stated; archive copy captured October 31, 2026.

$IDYAResearch updated November 4, 2026PDF · 20 pages

IDEAYA: Submitted NDA, OptimUM-010 Closure and Next Pipeline Tests

All eight analytical chapters: darovasertib and clinical denominators, IDE849, synthetic lethality, Q3 cash flows, Servier economics, equity, ownership, historical financing and risks. Daily price chart through November 3, after Q3.

$EWTXResearch updated November 5, 2026PDF · 19 pages

Edgewise: Q3 results, the Servier proceeds and the GRAND CANYON result

Dated research on Edgewise Therapeutics after its third-quarter 2026 results and Form 10-Q: $1,743.9 million of cash, cash equivalents and marketable securities at September 30, the Servier sale proceeds with $153.9 million in escrow, the contingent milestones of up to $1.1 billion after Servier’s November 3 GRAND CANYON announcement, the owned EDG-7500 and EDG-15400 programs and the planned Phase 3 start. Daily price chart through the November 4, 2026 close.

$CRDLArchive captured October 31, 2026PDF · 17 pages

Cardiol Therapeutics: cardiolrx and maveric

The report examines CardiolRx in recurrent pericarditis, the uncontrolled pilot evidence, the expanded pivotal MAVERIC trial and the separate ARCHER myocarditis program. It distinguishes blinded event observations from efficacy, and follows Canadian-dollar financial statements, subsequent U.S.-dollar financing and the assumptions behind runway guidance. Original research revision date not stated; this archive copy was captured October 31, 2026.

$AKBAResearch updated November 5, 2026PDF · 22 pages

Akebia: Q3 Results, VOCAL and the Vafseo Reimbursement Transition

Q3 results, VOCAL, Vafseo reimbursement and the debt refinancing condition.

$ZBIOResearch as of November 5, 2026PDF · 16 pages

Zenas BioPharma: third-quarter accounts, the obexelimab BLA and the lupus readout

Third-quarter 2026 revenue of $10.0 million, a net loss of $108.9 million and $647.1 million of cash and investments at September 30, with the obexelimab BLA under review to a May 27, 2027 target date and the EMA application validated. SunStone and ZB021 data are guided to the fourth quarter; debt, royalties, the at-the-market facility and dilution are stated at their own dates.

$VORResearch as of October 30, 2026PDF · 16 pages

Vor Biopharma: telitacicept and global development

The report examines Vor’s transition toward telitacicept, including the different autoimmune indications and the global Phase 3 development path. It separates published clinical evidence, future regulatory work and licensing economics, with attention to financing, prefunded warrants and the common-share claim.

$SNDXResearch updated November 4, 2026PDF · 20 pages

Syndax: Q3 Growth, cGVHD Timing and Shared Economics

All 20 original chapters: Q3 and nine-month finances, two marketed medicines, MAXPIRe, frontline studies, Incyte and Royalty Pharma economics, capital structure, risks and historical comparisons. Daily price chart through November 3, after the Q3 release.

$RZLTResearch updated October 30, 2026PDF · 17 pages

Rezolute: ersodetug evidence, separate HI indications and funding

Examines ersodetug’s insulin-receptor mechanism across congenital and tumor-associated hyperinsulinism, preserving sunRIZE’s failed prespecified endpoints alongside the small, uncontrolled upLIFT evidence. FDA pre-BLA dialogue, mid-December topline guidance and the later filing plan are separated from approval. June resources, annual cash consumption, pre-funded warrants, share authorization and contingent license milestones frame the funding and retained economics. Latest written revision: October 30; the header retains October 10.

$OGNResearch updated November 4, 2026PDF · 18 pages

Organon: Q3 2026, the Sun Pharma Transaction and Women’s Health

Dated research on Organon’s quarter and nine months ended September 30, 2026: the proposed $14 per share cash acquisition by Sun Pharma and its closing conditions, Nexplanon, MIUDELLA, VTAMA, biosimilars and established brands, operating cash generation, debt, the dividend, governance and risks. Daily price chart through the November 3, 2026 close.

$MYGNResearch updated November 6, 2026PDF · 20 pages

MYGN Stock Research: Myriad Genetics Q3 and Labcorp Prenatal Sale

Q3 results and revised guidance, the pending Labcorp prenatal transaction, operating cash flows, debt and diagnostics strategy, and the November 2 network intrusion disclosed in the November 5 Form 8-K.

$MNDRResearch as of October 30, 2026PDF · 15 pages

Mobile-health Network Solutions: digital healthcare and infrastructure

The report separates the established digital-healthcare activities from clinic software, Ghana plans and proposed Malaysian data-center development. It follows conditional funding, staged commitments, regulatory history and share structure, preserving the annual financial update alongside the older interim discussion.

$GUTSResearch updated November 6, 2026PDF · 16 pages

Fractyl Health: Revita’s REMAIN-1 Endpoints, De Novo Plans and the Reverse Split

Contrasts Revita’s pilot and pivotal six-month evidence with the outstanding one-year endpoint and planned De Novo submission, then examines cash consumption, financing choices and what the reverse split changes for shareholders.

$FBIOResearch as of October 30, 2026PDF · 16 pages

Fortress Biotech: Emrosi growth, portfolio monetization and common-share claims

Explores Fortress as a pharmaceutical asset platform rather than a single-drug developer, connecting Emrosi commercialization with ZYCUBO voucher monetization, royalties and externally funded partner programs. Dotinurad, oncology interests and other development assets are considered alongside consolidated cash, operating losses and the Oaktree repayment. Subsidiary ownership, preferred dividends, warrants and capital allocation frame the central question of how portfolio progress reaches each Fortress common share.

$EYPTResearch updated October 30, 2026PDF · 17 pages

EyePoint: DURAVYU, LUCIA and the DME Funding Test

DURAVYU’s wet AMD results and the COMO/CAPRI diabetic macular edema program, including noninferiority endpoints, supplemental injections and manufacturing requirements. Cash consumption and remaining clinical costs frame the financing challenge behind another pivotal program.

$CLYMResearch updated November 5, 2026PDF · 19 pages

Climb Bio Stock Research: Q3 Cash, CLYM116 and Budoprutug Updates

Q3 2026 cash and expenses, CLYM116 Phase 1 and NAVIGATE-2 updates, budoprutug PrisMN/SLE/ITP progress, share count and November 5 shelf filing.

$CLGNResearch as of October 30, 2026PDF · 21 pages

CollPlant and LightSolver: photonic computing, rhCollagen and funding

The archived report explains LightSolver’s laser-based computing architecture, the HLRS projected benchmark and the limits of translating emulator results to deployed hardware. It also examines Boeing and defense development work, CollPlant’s rhCollagen programs, historical cash use, acquisition consideration and conditional dilution.

$CBIOResearch as of October 30, 2026PDF · 17 pages

Crescent Biopharma: oncology pipeline and funding

The report examines Crescent’s oncology-development strategy, its principal clinical programs and the evidence expected from the next studies. It follows the rights and partnership structure, historical financial resources, cash consumption and potential dilution rather than treating a broad cancer market as established revenue.

$BTSGResearch as of October 30, 2026PDF · 15 pages

BrightSpring Health Services: care services and cash flow

The report examines BrightSpring’s pharmacy and provider-services model, demand drivers and the quality of reported growth. It follows margins, acquisitions, operating cash generation, debt and shareholder economics, with the original financial periods retained alongside the later quarterly update.

$AVTXResearch updated November 5, 2026PDF · 18 pages

Avalo Therapeutics: Q3 Results, Abdakibart and the Jefferies ATM

Q3 results, the LOTUS evidence and Phase 3 plans, funding guidance and the Jefferies sales agreement.

$AUPHResearch as of October 30, 2026PDF · 16 pages

Aurinia: Lupkynis growth, cash generation and capital allocation

Examines how LUPKYNIS sales and operating cash generation support Aurinia’s shareholder case, while distinguishing product growth from the cash retained after buybacks, equity awards and other commitments. The Teva settlement is assessed within its specific generic-entry limits, and the clinical discussion separates established AURORA evidence from PRESERVE and aritinercept development. Manufacturing leases, the Kezar transaction and contingent rights complete the analysis of franchise concentration, capital allocation and future spending.

$AMRXResearch updated November 4, 2026PDF · 21 pages

Amneal: Q3 Growth, Kashiv Debt and the Cash-Flow Test

All 23 original chapters: Q3 and nine-month finances, lanreotide, CREXONT, Kashiv, biosimilars, tirzepatide, manufacturing, debt, dilution, legal risks and historical comparisons. Daily price chart through November 3, after the Q3 release.

$ALNYResearch updated November 6, 2026PDF · 20 pages

Alnylam: Q3 Results, Repurchase Authorization and Commercial Leadership

Q3 results, the November repurchase authorization and commercial leadership transition.

$AGIOResearch updated November 6, 2026PDF · 19 pages

Agios: Q3 Results, AQVESME Uptake and Mitapivat Review

Q3 results, the Form 10-Q cash flows and share count, AQVESME uptake, the revised FDA review timetable and the rare hematology pipeline.

$ABEOResearch as of October 30, 2026PDF · 15 pages

Abeona Therapeutics: ZEVASKYN Manufacturing, Reimbursement and Launch Conversion

Follows ZEVASKYN from patient preparation through manufacturing release and reimbursed treatment, explaining why center expansion and early sales do not automatically resolve yield constraints, operating losses or financing dependence.

$ABCLResearch as of October 30, 2026PDF · 19 pages

AbCellera: ABCL635, Jazz Collaboration and the Cash Runway

ABCL635’s clinical evidence and ABCL575’s development plans sit beside the Jazz collaboration on multispecific antibodies. Cash burn, restricted balances, public funding and equity issuance are separated to assess how the proprietary pipeline is financed.

$XERSResearch updated November 6, 2026PDF · 22 pages

Xeris Biopharma: third-quarter accounts, Recorlev growth and the raised 2026 outlook

Third-quarter 2026 revenue of $107.2 million, Recorlev at $71.5 million, net income of $11.3 million and guidance raised to $395–405 million, with cash of $131.1 million at September 30. Recorlev safety and patent disputes, XP-8121’s pivotal plan, debt settlement, secured borrowing and dilution are stated at their own dates.

$VSTMResearch updated November 6, 2026PDF · 20 pages

Verastem: KRAS evidence, commercial launch and financing

The archive examines VS-7375 response denominators, confirmation status and the limitations of early oncology cohorts. It connects the approved low-grade serous ovarian cancer co-pack, the Novocure collaboration, financing and revenue-linked obligations with the next clinical and commercial evidence.

$TLXResearch as of October 29, 2026PDF · 18 pages

Telix: commercial imaging, the proposed ITM combination and regulatory execution

Connects Telix’s approved imaging franchise with its therapeutic pipeline, isotope supply and manufacturing strategy. Pixclara approval, the unresolved Zircaix manufacturing file and BiPASS development are analyzed as separate regulatory paths. Revenue growth and June cash flow are weighed against convertible debt, research spending and the proposed ITM combination, including share consideration, assumed debt, contingent milestones and closing conditions that determine the economics retained by existing holders.

$STOKResearch as of October 29, 2026PDF · 15 pages

Stoke: Dravet evidence, EMPEROR design and the RNA funding path

Archived research examines zorevunersen’s RNA mechanism, early Dravet observations and the controlled EMPEROR study. It separates cognitive and seizure endpoints, Biogen rights, OSPREY optic-atrophy development, September financial updates, equity funding and the sequence from clinical results to a possible regulatory submission.

$SRPTResearch updated November 6, 2026PDF · 28 pages

Sarepta: ELEVIDYS, PMO review and the RNA pipeline

The October 29 research snapshot examines marketed Duchenne therapies, liver safety, ESSENCE and FDA conversion review, early RNA programs, commercial results, debt, licensed economics and litigation.

$SLSResearch as of October 29, 2026PDF · 26 pages

SELLAS Life Sciences: REGAL final analysis, SLS009 and the funding behind the readouts

The full research covers GPS and the REGAL survival analysis, the SLS009 clinical and preclinical evidence, cash and operating burn, warrant-driven dilution, licensing obligations, institutional ownership, short positioning, scenarios, the dated catalyst framework, risks, primary sources and FAQ. Research and regular-session market reference: October 29, 2026.

$RIGLResearch updated November 6, 2026PDF · 13 pages

Rigel: VEPPANU launch, commercial cash flow and R289

Examines VEPPANU's approved breast-cancer indication and commercial launch alongside TAVALISSE, REZLIDHIA and GAVRETO, distinguishing product demand from licensing economics. The financial chapters connect operating cash generation with the upfront investment, supply commitments, revolver repayment, equity incentives and dilution. Early R289 response evidence is considered with patient selection, durability and safety, showing how a commercial business and an investigational pipeline create different tests for future value.

$RGNXResearch updated November 6, 2026PDF · 19 pages

REGENXBIO: third-quarter accounts, retinal readouts and the MPS hold

Third-quarter 2026 revenue, cash and runway frame the funding position into late Q4 2027, including the Sarepta settlement receipt collected in October. Sura-vec retinal evidence, the RGX-121 clinical hold and the RGX-202 filing calendar are separated from regulatory success, with royalties, operating cash use and the capital structure stated at their own dates.

$REPLResearch as of October 29, 2026PDF · 19 pages

Replimune: TUDRIQEV approval, launch economics and confirmatory risk

Traces TUDRIQEV’s regulatory reversals through accelerated approval, the approved melanoma population, administration requirements and safety qualifications. IGNYTE response evidence is separated from the survival obligation in IGNYTE-3 and the earlier RP2 pipeline. September resources, launch cash consumption, the going-concern conclusion, Hercules covenant alternatives, equity financing and pre-funded warrants explain how regulatory progress can coexist with commercial, clinical and dilution risk.

$PYPDResearch as of October 29, 2026PDF · 43 pages

PolyPid: D-PLEX100, SHIELD II and Azurity Payment Terms

D-PLEX100’s SHIELD I and SHIELD II evidence, the regulatory sequence and manufacturing responsibilities. The financial analysis follows historical cash, prelaunch inventory and Azurity payment conditions to test how commercialization could be funded.

$PROKResearch as of October 29, 2026PDF · 19 pages

ProKidney: PROACT 1 evidence, Kidney Week and the funding gap

Rilparencel’s autologous kidney-cell approach, Phase 2 limitations and PROACT 1 design frame the pivotal eGFR test. Kidney Week abstracts, going-concern uncertainty, June liquidity, paired share classes, the October shelf and dilution shape the financing case.

$PDSBResearch as of October 29, 2026PDF · 14 pages

PDS Biotechnology: PDS0301 signals, strategic funding and warrant exposure

PDS0301’s nonrandomized colorectal evidence and prostate data windows are assessed alongside the PDS0101 strategic reset. June cash, September PIPE conditions, debt redemption, resale registration and pre-funded warrants explain why financing and clinical confirmation remain separate tests.

$OCSResearch updated November 4, 2026PDF · 24 pages

Oculis: Q3 Financials, PREDICT-1, Privosegtor and Funding

All thirteen analytical chapters: post-DIAMOND scenarios, reporting and ordinary shares, privosegtor and ACUITY limits, PIONEER-1 and SPA, licaminlimab and PREDICT-1, retracted historical evidence, Accure and Novartis rights, Q3 and nine-month IFRS financials, cash and deposits, dilution, borrowing conditions, manufacturing and execution. Daily price and volume chart with SMA 50/200 on page 2 through November 3, dated historical financial analyses and eight complete FAQ answers.

$NVCRResearch as of October 29, 2026PDF · 15 pages

Novocure: Tumor Treating Fields and commercial expansion

The archive follows Tumor Treating Fields across established indications and proposed new markets. It examines revenue quality, adoption, reimbursement, clinical endpoints and operating costs, with financial resources and regulatory pathways kept separate from commercial success.

$NTLAResearch updated November 6, 2026PDF · 20 pages

Intellia Therapeutics: third-quarter accounts, the lonvo-z review and the ATTR trials

Third-quarter 2026 research and development expense of $83.3 million, a net loss of $127.5 million and $614.8 million of liquidity at September 30, with a guided runway into 2028 and a March 10, 2027 FDA target for lonvo-z. HAELO, Nex-z and the MAGNITUDE trials, the OrbiMed facility, dilution and ownership are stated at their own dates.

$MNKDResearch updated November 6, 2026PDF · 26 pages

MannKind: ReadyFlow launch, Afrezza and the cash behind commercial growth

The full research covers Furoscix and ReadyFlow, pediatric Afrezza, Tyvaso DPI partner economics and competitive settlement, clinical pipeline, revenue, cash and burn, debt, milestones, share dilution, ownership, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.

$MLYSResearch updated November 5, 2026PDF · 20 pages

MLYS Stock Research: Mineralys Q3, Lorundrostat and Launch Preparations

Q3 financial results, December 22 lorundrostat FDA target, clinical evidence, launch preparation and Tanabe payment obligations.

$MDAIResearch as of October 29, 2026PDF · 22 pages

Spectral AI: DeepView authorization, commercial launch and the funding bridge

The full research covers DeepView and the FDA order, clinical evidence and label expansion, commercialization, BARDA funding, NTAP reimbursement, cash and operating burn, Avenue debt, share dilution, institutional and insider ownership, scenarios, dated catalysts, risks, sources and FAQ. Research and regular-session market reference: October 29, 2026.

$MBOTResearch updated November 6, 2026PDF · 20 pages

Microbot Medical: LIBERTY orders, European timing and the economics of launch

The full research covers LIBERTY and its cleared use, clinical evidence, repeat orders, European timing, manufacturing, revenue, cash and historical burn, share dilution, ownership, filed litigation, scenarios, sources and FAQ. Research and regular-session market reference: November 6, 2026.

$LXRXResearch updated November 6, 2026PDF · 25 pages

Lexicon Pharmaceuticals: third-quarter accounts and the Q1 2027 ZYNQUISTA resubmission

Third-quarter 2026 revenue of $11.25 million, a net loss of $14.0 million and $183.2 million of cash and investments at September 30, with the ZYNQUISTA NDA resubmission moved to the first quarter of 2027 and the SONATA-HCM topline also guided there. INPEFA, LX9851 with Novo Nordisk, the capital structure and the Hercules covenant are stated at their own dates.

$KYMRResearch as of October 29, 2026PDF · 16 pages

Kymera: degrader evidence, pivotal plans and resources

The archive examines Kymera’s oral degrader programs, separating healthy-volunteer pharmacology from patient efficacy. It covers the KT-621 development pathway, KT-579 evidence, trial windows and September financial resources, together with spending and the risks behind management’s longer-term plans.

$IRDResearch as of October 29, 2026PDF · 15 pages

Opus Genetics: Viatris Presbyopia Economics, LCA5/BEST1 and Oberland Debt

Separates the Viatris presbyopia partnership’s milestones and royalties from LCA5 and BEST1 retinal gene-therapy evidence, assessing how trial execution, Oberland financing conditions, warrants and conversion rights affect common-share economics.

$SUPNResearch updated November 4, 2026PDF · 17 pages

Supernus (formerly Indivior): SUBLOCADE, the Completed Merger and Cash

Dated research on the Supernus merger completed November 2, 2026, the $8.13 special dividend, SUBLOCADE’s commercial franchise, the separate clinical study populations, cash generation, liabilities and transaction financing. Daily price chart through the November 3, 2026 close.

$INCYResearch as of October 29, 2026PDF · 18 pages

Incyte: Jakafi exposure, commercial diversification and acquisition economics

Connects Jakafi’s expected exclusivity loss with Opzelura, hematology and oncology launches, late-stage development and the economics of acquiring replacement growth. September results separate stronger sales from the Vega IPR&D charge, while earlier June comparisons retain their own periods and CMS-related accounting effects. Regulatory windows, early oncology evidence, cash resources, voting and ownership, competitive pressure and capital allocation frame the effort to sustain earnings beyond the largest product. Date label: October 29; includes October 30 updates.

$IMUXResearch as of October 29, 2026PDF · 16 pages

Immunic: Vidofludimus, ENSURE and Warrant Financing

Vidofludimus calcium’s multiple sclerosis evidence across ENSURE, CALLIPER and extension studies, including endpoint and selection-bias questions. The financial sections examine cash burn, February financing terms and the dilution mechanics of warrants and the reverse split.

$IMRXResearch updated October 29, 2026PDF · 14 pages

Immuneering: pancreatic survival, MAPKeeper 301 and the cash runway

Assesses atebimetinib’s pancreatic-cancer survival signal and exploratory analyses while explaining why longer follow-up and a controlled comparison remain essential. MAPKeeper 301’s enrollment plan, the expanded patient target and the separate lung-cancer program are placed on distinct evidence timelines. September financial resources, historical operating cash use and runway guidance are reconciled with warrants, share issuance and financing capacity, linking the clinical development plan to the capital needed to complete it.

$HUMAResearch as of October 29, 2026PDF · 21 pages

Humacyte: Symvess launch, dialysis evidence and the funding path

The full research covers Symvess, V012 and V007 dialysis evidence, the sBLA path, CTEV, hospital adoption, product sales, cash and burn, Avenue debt and conversion rights, completed financing, warrant dilution, ownership, filed litigation, listing requirements, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.

$GMABResearch as of November 5, 2026PDF · 17 pages

Genmab: nine-month accounts, three late-stage readouts and acquisition debt

Nine-month 2026 revenue of $3,238 million, up 22%, operating profit of $986 million, net profit of $698 million and $1,860 million of cash at September 30, against $4,992 million of borrowings. The report compares LiGeR-HN1, RAINFOL-02 and EPCORE DLBCL-2 while preserving their different populations and endpoints, and covers the European and Japanese epcoritamab approvals, the two new Phase 3 trials in colorectal cancer, the royalty base and the Merus funding.

$ETONResearch updated October 29, 2026PDF · 12 pages

Eton: specialty sales, acquisitions and cash conversion

The report examines HEMANGEOL and IMPAVIDO within Eton’s specialty-medicine portfolio and commercial infrastructure. It follows acquisition obligations, product economics, cash conversion and development milestones, setting revenue growth against the financing and execution needed to sustain it.

$DYNResearch updated November 6, 2026PDF · 16 pages

Dyne Therapeutics Stock Research: Q3 Cash, PDUFA and ACHIEVE Path

Q3 2026 cash and runway, R&D and G&A spend, net loss, z-rostudirsen PDUFA January 21, 2027, ACHIEVE REC Q1 2027 and Phase 3 FORZETTO/HARMONIA updates.

$DRMAResearch as of October 29, 2026PDF · 13 pages

Dermata: Tome consumer demand, cosmetic evidence and financing

Archived analysis of the shift from the former prescription program to Tome skincare and the economics required after commercial availability. It examines the small open-label cosmetic study, the new acne-study design, retail pricing, June cash use, August financing, warrant conditions and resale-share supply.

$DFTXResearch as of October 29, 2026PDF · 18 pages

Definium Therapeutics: DT120 evidence, supervised treatment and the funding bridge

DT120’s pivotal evidence is examined across generalized anxiety disorder and major depression, with separate attention to Panorama, Voyage, Emerge and the Ascend replication study. The dossier discusses functional unblinding, long-term safety and retreatment, FDA preparation, controlled-substance scheduling and the capacity and reimbursement required for supervised dosing. June financing, cash consumption, employee options and the enlarged share base frame the resources and ownership risks behind that development path.

$CTNMResearch updated November 4, 2026PDF · 22 pages

Contineum: Q3 Financials, PIPE-791, PROPEL-IPF and Dilution

All sixteen analytical chapters plus falsifiers: PIPE-791 and PROPEL-IPF design, PIPE-307 primary-endpoint misses, earlier occupancy and pain evidence, the LPA1 class, Q3 and nine-month earnings, program spending, cash and runway, J&J licensing, dilution and two share classes, ownership, insider transactions, valuation arithmetic and sentiment limits. Daily price and volume chart with SMA 50/200 on page 2 through November 3, plus eight complete FAQ answers; the historical H1 liquidity chart and dated analysis included.

$CRDFResearch as of October 29, 2026PDF · 26 pages

Cardiff Oncology: Onvansertib, Phase 3 funding and the Nerviano agreement

A dated review of onvansertib and CRDF-004, the registrational plan, the Nerviano settlement and license obligations, financial resources, going concern, equity dilution, governance and clinical-development risks.

$CODXResearch as of October 29, 2026PDF · 19 pages

Co-Diagnostics: PCR authorization, installation economics and funding

Archived research separates point-of-care PCR development, environmental Vector Smart installations, Indian tuberculosis testing and Saudi manufacturing plans. It examines clinical and workflow evidence, FDA and CLIA review, the HPV study’s limited scope, recurring consumable demand, operating losses, loan funding and dilution.

$CELCResearch as of October 29, 2026PDF · 16 pages

Celcuity: REVTORPYK Launch, VIKTORIA-1 and Pfizer Economics

REVTORPYK’s label, VIKTORIA-1 efficacy and tolerability, and the commercial launch are examined alongside Pfizer milestone and royalty obligations. The balance-sheet discussion explains how convertible financing and launch costs affect shareholder economics.

$CADLResearch updated November 6, 2026PDF · 18 pages

Candel Therapeutics: Prostate Phase 3, BLA Manufacturing and Conditional Funding

Aglatimagene’s prostate trial evidence and manufacturing validation connect to the proposed BLA pathway, with AURORA and linoserpaturev providing separate development questions. Spending, equity dilution and financing contingent on approval frame the cost of advancing the platform.

$BHVNResearch as of October 29, 2026PDF · 16 pages

Biohaven: BHV-1530 evidence, partial hold and licensing cash

BHV-1530’s early oncology observations are examined alongside neuroscience and immunology programs, opakalim’s partial enrollment hold, licensing agreements, quarterly cash and debt, pending contractual payments and the dilution required to fund a broad clinical portfolio.

$BCRXResearch updated November 6, 2026PDF · 18 pages

BioCryst: Q3 Commercial Profit, Channel Inventory and the HAE Pipeline

Q3 results, 10-Q cash flows and debt, share counts, CareMed inventory, ORLADEYO and HAE pipeline milestones.

$BBIOResearch as of October 29, 2026PDF · 44 pages

BridgeBio: Attruby revenue, three applications and senior capital claims

Attruby’s product revenue, partner royalties and license milestones are traced through quarterly accounts and the economics retained by BridgeBio and its subsidiaries. Three applications are examined alongside clinical denominators, registry distinctions and observational comparison limits. Convertible notes, program-level royalty sales, cumulative preferred equity, repurchases, ownership and potential dilution show how commercial progress interacts with senior claims. September-quarter updates are preserved beside earlier June detail, without presenting all figures as one reporting period.

$ATYRResearch updated October 29, 2026PDF · 14 pages

aTyr Pharma: the next efzofitimod trial, financing and the reverse split

EFZO-FIT’s missed primary endpoint frames aTyr’s new pulmonary-sarcoidosis study and separate EFZO-CONNECT readout. The report examines June resources, restructuring, additional Phase 3 financing, the October reverse split and early ATYR0101 and ATYR2810 development.

$ARTVResearch as of October 29, 2026PDF · 20 pages

Artiva: AlloNK discontinuation, strategic alternatives and residual resources

Artiva’s AlloNK discontinuation and strategic review supersede earlier clinical plans. The report preserves safety and durability disclosures, preliminary September resources, the wind-down filing, historical financing, dilution and the limits of assuming a liquidation return. Editorial review: October 29; separate October 27 company-news label retained.

$ARTLResearch as of October 29, 2026PDF · 12 pages

Artelo: early clinical evidence and financing risk

The report separates Artelo’s human pain-development programs from preclinical obesity observations and patent filings. It examines clinical design, potential differentiation, cash consumption, reverse-split mechanics and warrants, with scenarios tied to evidence rather than promotional comparisons.

$ARDXResearch updated November 4, 2026PDF · 32 pages

Ardelyx: Q3 Cash Conversion, IBSRELA Growth, ACCEL and Patents

All 22 analytical chapters: Q3 and nine-month earnings, cash conversion, dated Q2 financials, IBSRELA access, XPHOZAH reimbursement, ACCEL trial design and enrollment, RDX10531, patents, secured debt and covenants, equity dilution, ownership, filed litigation and risks. Daily candles, volume and SMA 50/200 on page 2 through November 3, before the Q3 release.

$AMRNResearch as of October 29, 2026PDF · 19 pages

Amarin: VASCEPA cash conversion, partner economics and EMT2 evidence

The full research covers VASCEPA and VAZKEPA, third-quarter earnings, liquidity and working-capital quality, contractual obligations, REDUCE-IT and EMT2 evidence, international partners, the Hikma settlement and remaining legal matters, ADSs and share dilution, ownership, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.

$ALLOResearch updated November 6, 2026PDF · 17 pages

Allogene Therapeutics: ALPHA3 evidence, safety history and cell-therapy funding

Separates ALPHA3’s small molecular interim groups from blinded survival endpoints, documenting the closed ALLO-647 arm, safety attribution and subsequent design changes. ALLO-329 and the broader pipeline retain their own evidence and development windows. June investment resources, cash-flow timing, state research funding, the April equity raise, shelf financing capacity, ownership denominators and leadership transitions connect clinical execution to runway and potential dilution without treating cash as a share-price floor.

$ADCTResearch updated November 5, 2026PDF · 18 pages

ADCT: ASH data, preliminary September figures and a closed financing

Dated research on ADC Therapeutics after its November 4 Form 8-K: the full LOTIS-5 results and their benefit-risk question, LOTIS-7 with glofitamab (88.7% ORR in 97 patients) and marginal-zone lymphoma data, preliminary third-quarter ZYNLONTA sales of about $21 million and $189.2 million of cash, the PIPE and loan prepayment closed October 22, royalties, warrants and the proposed move to Delaware. Daily price chart through the November 4, 2026 close.

$VNDAResearch as of October 28, 2026PDF · 18 pages

Vanda Pharmaceuticals: HETLIOZ, Imsidolimab and the Commercial Cash Test

HETLIOZ’s delayed sleep-phase study, imsidolimab’s regulatory path and the mix of Fanapt, PONVORY and newer products. Revenue timing, launch execution and historical liquidity connect the clinical portfolio to the cost of building sales.

$VKTXResearch as of October 28, 2026PDF · 15 pages

Viking Therapeutics: VK2735, VANQUISH/SUNRISE and Convertible Financing

Covers injectable VK2735 maintenance results, the VANQUISH and oral SUNRISE programs, and the financing behind late-stage obesity development, separating trial completion expectations from readout dates and potential dilution.

$VIRResearch updated November 5, 2026PDF · 21 pages

Vir Biotechnology: Q3 cash, the ECLIPSE 1 window and the oncology platform

Dated research on Vir after its third-quarter 2026 results and corporate update: about $901.3 million of cash, equivalents and investments at September 30, roughly $106 million of quarterly operating cash use, the $90 million Gilead receipt in October and the share count at October 28, with ECLIPSE 1 topline still guided to the fourth quarter of 2026 and VIR-5500 pivotal trials planned for 2027. The chapters cover the SOLSTICE evidence, ECLIPSE 1, 2 and 3, PRO-XTEN oncology and the Gilead, Astellas, Norgine, Sanofi and Alnylam economics. Daily price chart through the November 4, 2026 close.

$URGNResearch updated November 5, 2026PDF · 17 pages

UroGen: third-quarter results, the September-quarter 10-Q, ZUSDURI growth and financing

Dated research on UroGen after the November 4, 2026 third-quarter results and Form 10-Q: ZUSDURI sales of $68.0 million, operating income of $8.3 million, the reduced JELMYTO guidance, $90.5 million of cash and securities, nine-month cash use, receivables, the Pharmakon loan and RTW revenue-linked payments, the funding statement in the 10-Q, with scenarios and the evidence that could challenge the assessment. Daily price chart through the November 4, 2026 close.

$SMMTResearch updated November 6, 2026PDF · 22 pages

Summit Therapeutics: ivonescimab evidence, FDA review and financing

The November 5 edition covers third-quarter 2026 results, the November 14 FDA goal date, original and later HARMONi analyses, global trials, the AstraZeneca investment, the authorized-share vote and resale registration, dilution, governance and the Health Score.

$RLAYResearch updated November 6, 2026PDF · 15 pages

RLAY Stock Research: ReDiscover-2 Enrollment, ReInspire and Q3 Financials

Q3 financials, the ReDiscover-2 enrollment estimate, December ReInspire data, the TIE2 program and Elevar licensing.

$RAPPResearch updated November 4, 2026PDF · 26 pages

Rapport: Q3 Cash Flow, Closed Financing and the RAP-219 Pivotal Tests

All twenty analytical chapters and nine historical analytical answers, including TARPγ8/AMPA biology, the randomized mania result and its limitations, FOS evidence, FOCUS pivotal execution, long half-life, LAI and RAP-641, complete Q3/9M accounts and cash flow, September versus later estimated resources, closed equity and private placement, final physical note settlement, ATM use, Tenacia, ownership, management, competition and dated scenarios. Daily price/volume chart with SMA 50/200 on page 2, five-pillar Health Score and eight complete current FAQ answers.

$QUREResearch updated November 4, 2026PDF · 23 pages

uniQure: Q3 Accounts, AMT-130 Priority Review and the Confirmatory Test

All twenty-two analytical chapters: Huntington’s biology, AMT-130 trial design, distinct three- and four-year datasets, safety and external-control limitations, FDA history, Priority Review and PDUFA, confirmatory design, UK filing, manufacturing and launch, Q3 and historical financials, complete cash flow, conditional debt and royalty obligations, shares, awards, ownership, HEMGENIX, wider pipeline, competition and risk scenarios. Daily price/volume chart with SMA 50/200 on page 2, historical revenue graphic and eight complete current FAQ answers.

$PRMEResearch as of October 28, 2026PDF · 13 pages

Prime Medicine: prime editing and liver programs

The report examines prime editing, the liver-development strategy and the separate PM359 regulatory evidence. It distinguishes preliminary clinical observations, company plans and draft regulatory guidance, then follows cash consumption, financing needs and the time available to reach the next data.

$PGENResearch updated November 6, 2026PDF · 15 pages

PGEN: September 30 quarterly report, PAPZIMEOS collections and a new competitor

Dated research on Precigen after its Form 10-Q for the quarter ended September 30, 2026: $72.9 million of PAPZIMEOS net revenue, $35.8 million of net income, about $11.9 million of quarterly operating cash flow, $96.5 million of receivables on 127-day terms and $51.0 million of cash and investments against $100 million of debt. The chapters cover the launch, the October 30 FDA approval of a competing RRP therapy, the EMA review, dilution and AdenoVerse. Daily price chart through the November 6, 2026 close.

$ORICResearch as of October 28, 2026PDF · 18 pages

ORIC: enozertinib evidence, rinzimetostat validation and pivotal funding

Examines enozertinib through mutation groups, systemic and intracranial responses, patient denominators and the limits of early single-arm evidence. Rinzimetostat’s mechanism and Himalayas-1 randomized design are assessed separately from biomarker responses and competitor studies. June cash and investments, rising pivotal costs, licensed economics, manufacturing obligations and potential dilution connect the two oncology programs with the resources and evidence needed to reach a useful regulatory and commercial outcome.

$NVOResearch updated November 4, 2026PDF · 19 pages

Novo Nordisk: nine-month results, the raised outlook and CagriSema

Dated research on Novo Nordisk’s first nine months of 2026 and the outlook raised on November 4, 2026, semaglutide’s commercial base, CagriSema’s mixed evidence, the Wegovy pill, competition, U.S. list-price cuts from January 1, 2027, manufacturing requirements, cash flow and debt. Danish-krone accounts are kept separate from the U.S.-dollar ADR. Daily price chart through the November 3, 2026 close.

$MTVAResearch as of November 5, 2026PDF · 14 pages

MetaVia: the DA-1726 Part 3B interim data and the path to Phase 2

Part 3B interim data reported on November 5, 2026 showed a 68% placebo-adjusted liver-fat reduction, 13.5% placebo-adjusted weight loss and HbA1c from 5.79% to 5.33% after 16 weeks. The Phase 1 design, vanoglipel, cash and monthly consumption, the Dong-A obligation, warrants and at-the-market capacity are stated at their own dates.

$LGVNResearch as of October 28, 2026PDF · 17 pages

Longeveron: laromestrocel after ELPIS II and the financing test

Archived research on the ELPIS II primary endpoint miss, subsequent cardiac-event analyses and the separate frailty and Alzheimer’s programs. The report examines strategic alternatives, June liquidity, preferred-stock conversion exposure and the financing conditions tied to clinical progress. It preserves the differing dates and denominators of the September and October disclosures.

$KPTIResearch updated November 4, 2026PDF · 29 pages

Karyopharm: Chapter 11, the Ayrmid Bid and the Selinexor Pipeline

Dated research on the November 2, 2026 Chapter 11 filing, the Restructuring Support Agreement, DIP financing, the Ayrmid stalking horse bid and proposed court dates, treatment of common stock under the proposed plan, XPOVIO, SENTRY and the myelofibrosis sNDA, financial obligations, management, competition and risks. Daily price chart on page 2 through November 3, after the filing.

$KNSAResearch as of October 28, 2026PDF · 23 pages

Kiniksa: ARCALYST economics, event-driven studies and four share classes

The archived research follows ARCALYST adoption, collaboration obligations and the cash generated by the commercial franchise. It examines KPL-387 interval evidence, the event-driven PASTORALE design, KPL-1161 plans, supply and exclusivity risks, four-class ownership, voting rights and the distinction between listed float and total capital.

$IOVAResearch as of November 5, 2026PDF · 31 pages

Iovance Biotherapeutics: record third-quarter revenue, Amtagvi and the expansion cohorts

Third-quarter 2026 revenue of about $122 million, up about 80%, U.S. Amtagvi revenue of about $102 million, gross margin of about 60% and the net loss cut to $22.3 million, with guidance of $410–420 million reaffirmed. The Amtagvi commercial ramp, manufacturing, TILVANCE-301, the lung-cancer and sarcoma cohorts, cash and dilution are stated at their own dates.

$ICUResearch as of October 28, 2026PDF · 24 pages

SeaStar Medical: QUELIMMUNE, adult AKI and the funding bridge

Dated research on pediatric QUELIMMUNE, hospital codes and sales, the adult NEUTRALIZE-AKI trial, clinical evidence, cash, financing, warrants, ownership and risks.

$HIMSResearch as of October 28, 2026PDF · 16 pages

Hims & Hers: growth quality, Eucalyptus and financial obligations

This dated report examines the second-quarter revenue mix, margin decline and cash conversion as branded weight-loss medicines and Eucalyptus enter the business. It details acquisition accounting and future payments, convertible notes, working capital, legal exposure and the governance structure, with scenarios and financial benchmarks for later results.

$HELPResearch as of October 28, 2026PDF · 23 pages

Helus Pharma: APPROACH, HLP003 and HLP004 development

A dated review of the adjunctive depression program, APPROACH and the pivotal evidence test, HLP004 in anxiety, treatment-delivery considerations, finances, equity claims, governance and clinical-development risks.

$CRSPResearch updated November 3, 2026PDF · 18 pages

CRISPR Therapeutics: Q3 Earnings, CASGEVY, CTX310 and Zugo-cel

Q3 and nine-month results, CASGEVY collaboration economics, pediatric approvals, the clinical pipeline, cash use, convertible debt, dilution and historical comparisons. Daily price chart through November 2, before the earnings release.

$CMPSResearch updated November 4, 2026PDF · 17 pages

Compass: COMP360 NDA, Q3 Cash and the Supervised-Launch Test

All 12 analytical chapters: controlled trials, one-year open-label data, safety, PTSD, treatment capacity, Q3 cash flows, warrant accounting, debt, dilution, ownership and historical comparisons. Daily price chart through November 3, after Q3.

$BEAMResearch updated November 4, 2026PDF · 21 pages

Beam: Q3 Funding, Risto-cel Filing and the BEAM-302 Pivotal Test

All 15 analytical chapters, historical charts, Q3 finances, cash burn, conditional debt, ATM, risto-cel, BEAM-302/301/304, partnerships, competitors and risks. Daily price chart through November 3, after Q3.

$BCTXResearch updated November 6, 2026PDF · 18 pages

BriaCell: Bria-IMT, the survival trial and financing constraints

Analysis of Bria-IMT, the randomized Bria-ABC survival study and the distinction between DSMB monitoring, early clinical observations and an efficacy readout. It covers manufacturing arrangements, the wider cell-therapy pipeline, cash consumption, financing and dilution. The November 6 edition adds the four SITC 2026 preclinical posters, the November 6 close and the calculated equity value; April, July and October references are retained as history with their own dates.

$AVXLResearch as of October 28, 2026PDF · 31 pages

Anavex: Blarcamesine, the Rett program and the regulatory record

A dated review of blarcamesine in Alzheimer’s disease, Rett syndrome and Fragile X, the European application withdrawal, U.S. development plans, cash and financing, equity dilution, governance, legal proceedings and clinical risks.

$ARQTResearch updated November 5, 2026PDF · 20 pages

ARQT Stock Research: ZORYVE Sales, Q3 Results and the FDA Calendar

ZORYVE sales, Q3 financial results, revised guidance, ATM capacity, management changes and clinical milestones.

$ANNXResearch as of October 28, 2026PDF · 15 pages

Annexon: ARCHER II stages, GBS evidence and financing conditions

ARCHER II’s functional endpoint and staged analyses are assessed alongside the earlier ARCHER failure, ocular safety, GBS evidence and ANX1502. June liquidity, Oxford borrowing, conditional tranches, warrants and spending distinguish development capacity from clinical success. Last review: October 28; information-current label: October 19.

$ZURAResearch as of October 27, 2026PDF · 18 pages

Zura Bio: tibulizumab endpoints, cash and pre-funded dilution

Tibulizumab’s IL-17A and BAFF rationale, TibuSHIELD and TibuSURE trial endpoints, shared clinical risks, historical cash, pre-funded warrants and the separately dated October shelf and quarterly updates explain the development and financing case.

$WORXResearch as of October 27, 2026PDF · 18 pages

SCWorx: data operations, Nasdaq and financing

The archive examines SCWorx’s healthcare-data business and the economics of new software workflows. It sets revenue, losses and liquidity against Nasdaq monitoring, warrant exercises and resale registration, explaining dilution and the limits of interpreting registration capacity as company cash.

$VTVTResearch as of October 27, 2026PDF · 17 pages

vTv Therapeutics: cadisegliatin evidence, CATT1 and per-share economics

Archived analysis of cadisegliatin’s mechanism, the earlier randomized and insulin-withdrawal studies, the CATT1 design and its distinct hybrid closed-loop pilot. It examines licensing accounting, normalized historical cash use, pre-funded warrants, territorial rights and the difference between enrollment and pivotal efficacy evidence.

$VERAResearch as of October 27, 2026PDF · 21 pages

Vera Therapeutics: TRUTAKNA, ORIGIN 3 and launch economics

The October 27 research snapshot covers accelerated approval, final randomized ORIGIN 3 efficacy, exploratory PIONEER observations, launch execution, Oxford financing, licensed economics and dilution.

$SRRKResearch as of October 27, 2026PDF · 28 pages

Scholar Rock: ISEMBYLD launch, fracture risk and conditional liquidity

Explores ISEMBYLD’s SMA approval through the SAPPHIRE evidence, the approved dose, nominal statistical findings and the limits of extrapolating from the studied population. Fracture warnings, post-marketing obligations and the company’s corrective disclosure receive detailed treatment alongside launch access, infusion logistics and the European regulatory path. June financial statements, the Blue Owl facility, minimum-cash requirements and ATM dilution show how a funded balance sheet intersects with the costs and uncertainties of commercialization.

$SENSResearch as of October 27, 2026PDF · 17 pages

Senseonics: Eversense adoption, pump integration and commercial cash use

Eversense 365 commercialization, pump partnerships, real-world evidence and the Gemini and Freedom pipeline are examined against revenue growth and raised guidance. The financial analysis separates unrestricted liquidity, Hercules debt, cash consumption, pre-funded warrants and issuance capacity.

$PTGXResearch as of October 27, 2026PDF · 13 pages

Protagonist: partnered medicines and recurring royalties

The archive examines the approved partnered programs and the distinction between milestone income and recurring royalties. It connects clinical evidence, partner economics, internal peptide development, cash use and repurchases with the financial disclosures needed to establish a durable earnings base.

$PRAXResearch as of October 27, 2026PDF · 17 pages

Praxis Precision Medicines: trial evidence, two FDA reviews and the launch transition

Relutrigine and ulixacaltamide are assessed through their different neurological indications, trial designs, regulatory histories and potential commercial requirements. The analysis examines Essential 3 attrition and tolerability, EMBOLD and EMERALD evidence, antisense development and the implications of the vormatrigine program setback. Historical cash, operating spending, launch preparation, warrants, awards and financing capacity frame the resources and dilution behind a transition toward possible first products.

$ORKAResearch as of October 27, 2026PDF · 17 pages

Oruka: controlled psoriasis evidence, durability and common-equivalent dilution

Follows ORKA-001 from early dosing through EVERLAST-A and the randomized EVERLAST-B Week 16 results, distinguishing within-study evidence from cross-trial comparisons. Durability, dose selection, safety and competition frame the potential advantage of longer treatment intervals. ORKA-002, hidradenitis suppurativa and earlier optionality are assessed separately, while licensing, manufacturing, June liquidity, July financing, preferred conversion, pre-funded warrants and employee awards determine the resources and ownership cost of pivotal development.

$NYXHResearch updated October 27, 2026PDF · 12 pages

Nyxoah: Genio evidence, U.S. launch and euro financing

Research on the Genio neuromodulation system, DREAM, ACCCESS and BREATHE evidence, and the path from clinical outcomes to commercial implant activity. It examines reduced revenue guidance, euro cash consumption, debt and convertible obligations, dilution and the pending CCC indication-expansion supplement.

$NKTRResearch as of October 27, 2026PDF · 14 pages

Nektar Therapeutics: REZPEG evidence, selected responders and pivotal funding

Compares randomized dermatitis evidence with the missed original alopecia primary analysis and later selected-responder durability data, emphasizing the five-of-eight denominator. The ZENITH development roadmap separates trial initiation, future pivotal results and a conditional filing path. June cash and investment categories, historical operating consumption, research prepayments, financing dilution and the uncollected Lilly verdict explain the resources and obligations behind a broader Phase 3 program without turning cash arithmetic into management guidance.

$NAUTResearch as of October 27, 2026PDF · 17 pages

Nautilus Biotechnology: Voyager, Tau Proteoforms and ATM Dilution

Connects the Tau proteoform study with paid Early Access services and Voyager’s instrument roadmap, examining the adoption hurdle, limited initial revenue and dilution implied by a potentially large ATM financing program.

$MRNAResearch updated November 6, 2026PDF · 16 pages

Moderna: INTerpath-001 melanoma data, Canadian respiratory approvals and the capital position

Detailed Phase 3 INTerpath-001 results (recurrence-free survival HR 0.58, distant-metastasis-free survival HR 0.62) presented at ESMO, alongside Health Canada authorization of mFLUSIVA and mCOFLU for adults 50 and older on November 5, 2026. June liquidity of $6.910 billion, the $3.0 billion convertible issued in September, the $815 million second-quarter operating loss and the shared Merck oncology economics frame the path to commercialization. Third-quarter results were scheduled for November 6, 2026.

$LFWDResearch as of October 27, 2026PDF · 14 pages

Lifeward: rehabilitation sales, working capital and convertible financing

Examines ReWalk and AlterG commercial recovery alongside reimbursement, distribution and the evidence supporting rehabilitation devices. June cash, operating consumption, receivables and purchase commitments show why revenue growth must translate into collections. The report unpacks secured notes, conditional capital, pre-funded securities, warrants and the shareholder vote on issuance limits, while separating the experimental oral-insulin program and longer-term product roadmap from the existing device business.

$LEGNResearch as of October 27, 2026PDF · 20 pages

Legend Biotech: CARVYKTI economics, durability and the LB2501 evidence

Explains how CARVYKTI sales reach Legend through its collaboration economics, connecting commercial growth with the company’s income statement and cash flow. Long-term CARTITUDE evidence, frontline trial design and neurological safety are examined alongside the much smaller, early LB2501 dataset and the pipeline beyond CARVYKTI. Balance-sheet resources, financing and dilution are considered with manufacturing, treatment access and competition, while ADS arithmetic prevents ordinary shares and depositary units from being treated as interchangeable.

$KRROResearch as of November 5, 2026PDF · 16 pages

Korro Bio: third-quarter accounts, the ANCHOR trial and the Novo termination

Third-quarter 2026 research and development expense of $12.1 million, a net loss of $17.5 million and $124.8 million of liquidity at September 30, with a guided runway into the second half of 2028. KRRO-121 in urea cycle disorders, KRRO-111 in AATD, the KRRO-110 reset and the November 3 termination of the Novo Nordisk collaboration are stated at their own dates.

$KODResearch as of October 27, 2026PDF · 23 pages

Kodiak Sciences: Zenkuda, DAYBREAK, PEAK and the funding path

Dated research on the Zenkuda recovery, GLOW and DAYBREAK, KSI-101 and MESI, clinical scenarios, finances, capital structure, management, competition and risks.

$IBRXResearch as of October 27, 2026PDF · 50 pages

ImmunityBio: ANKTIVA, QUILT data and the capital structure

Complete dated research on ANKTIVA, approved uses, clinical programs, commercial execution, cash, dilution, litigation, governance and regulatory risks.

$GERNResearch updated November 5, 2026PDF · 50 pages

Geron: Q3 RYTELO Profitability and the Business After IMpactMF

Q3 results and 10-Q cash flows, debt and share counts, RYTELO demand and the ASH poster program.

$DNTHResearch updated November 5, 2026PDF · 22 pages

DNTH Stock Research: Claseprubart, MoMeNtum and Q3 Financials

Q3 financials, claseprubart and MoMeNtum, CAPTIVATE timing, the DNTH212 and DNTH312 pipeline, and dilution.

$CORTResearch updated November 4, 2026PDF · 21 pages

Corcept: Q3 Earnings, Lifyorli, MONARCH and the December FDA Decision

All 11 numbered analytical chapters and the scenario tests: commercial franchises, approved label, CATALYST and screening, Q3 and nine-month earnings, tax and cash flow, securities, compensation and repurchases, leadership, ownership, historical call analysis and regulatory catalysts. Updated BELLA, MONARCH and ALS evidence. Daily price and volume chart with SMA 50/200 on page 2 through November 3.

$ARWRResearch updated November 4, 2026PDF · 16 pages

Arrowhead: REDEMPLO, ARO-MAPT and the November 2 refinancing

Dated research on Arrowhead covering REDEMPLO’s launch economics and SHASTA evidence, ARO-MAPT biomarker findings, the plozasiran broader-indication pathway, partnership receipts, the priority review voucher and the November 2, 2026 term-loan refinancing. Daily price chart through the November 3, 2026 close.

$AQSTResearch updated November 4, 2026PDF · 29 pages

Aquestive: Anaphylm Review, Q3 Cash Flows and LIBERVANT Economics

All 25 analytical chapters: Anaphylm review history, human factors and pharmacokinetics, launch readiness, Q3 and nine-month earnings, cash flows, historical financials, debt, royalty claims, equity dilution, LIBERVANT applications and Eton economics, AQST-108, governance, ownership, competition and risks. Daily price chart on page 2 through November 3, before the after-close results.

$ANLResearch as of October 27, 2026PDF · 14 pages

Adlai Nortye: cancer pipeline and financing

The report examines Adlai Nortye’s oncology platform, the evidence for its clinical candidates and the limits of extrapolating early or combination data. It follows development milestones, licensing commitments, financial resources and the dilution and execution risks behind the pipeline.

$TVTXResearch updated November 3, 2026PDF · 21 pages

Travere Therapeutics: Q3 FILSPARI growth, cash conversion and pipeline

Updated research integrates Q3 2026 sales, patient-start forms, operating results, cash flows, royalty accounting and convertible debt with FILSPARI label limits, clinical evidence, civorebrutinib and HARMONY. Includes the dated Q2 2026 comparisons and the full company analysis. Includes a six-month price and volume chart with 50- and 200-session simple moving averages.

$RXRXResearch updated November 3, 2026PDF · 19 pages

Recursion: Q3 Funding, REC-4881 and Clinical Evidence

All 18 original chapters: Q3 and nine-month finances, TUPELO and DAHLIA, pipeline priorities, partnerships, data economics, dilution, leadership, risks and historical comparisons. Daily price chart through November 3, after the Q3 release.

$OTLKResearch as of October 26, 2026PDF · 26 pages

Outlook Therapeutics: LYTENAVA launch, cash runway and capital risks

The October 26 research snapshot examines the FDA and clinical history, U.S. launch and pricing, reimbursement, cash, Atlas obligations, European commercialization, dilution, ownership, listing and legal risks.

$OMERResearch as of October 26, 2026PDF · 45 pages

Omeros: YARTEMLEA launch, European refusal and post-repurchase liquidity

The October 26 research snapshot examines TA-TMA evidence, the U.S. launch and reimbursement, the European refusal, competition, finances, convertible notes, the Novo transaction, pipeline and risks.

$OCULResearch as of October 26, 2026PDF · 20 pages

Ocular Therapeutix: AXPAXLI filing plans, repeat dosing and funding

The October 26 report examines SOL-1 evidence and its comparator, the proposed NDA package, SOL-R, retina competition, DEXTENZA, cash runway, Barings debt, dilution and ownership.

$OCGNResearch updated November 5, 2026PDF · 26 pages

Ocugen: the December 22 share vote, the cash-settled notes and the September-quarter 10-Q

Dated research on Ocugen after its November 4, 2026 third-quarter update and Form 10-Q: the December 22 special meeting on 250 million new shares, the $130 million convertible notes that must be settled in cash until it passes, $84.6 million of cash and investments at September 30 and the going-concern conclusion repeated in the 10-Q, the OCU400 Provisional Approval and Priority Designation from the Longevity and Regenerative Therapies (LARTA) Board of The Bahamas, the OCU400, OCU410 and OCU410ST programmes, ownership, legal matters and the catalyst map. Daily price chart through the November 4, 2026 close.

$NVAXResearch updated November 6, 2026PDF · 30 pages

Novavax: Q3 Results, Sanofi Milestones and Seasonal Vaccines

Q3 results and 2026 financial outlook, the earned Sanofi milestone, the Form 10-Q cash flows, convertible notes and share count, seasonal vaccines and partner economics.

$NRXPResearch as of October 26, 2026PDF · 42 pages

NRx Pharmaceuticals: Ketamine review, clinics, funding and dilution

Complete dated research on the generic and branded ketamine pathways, FDA correspondence, cash and burn, capital structure, HOPE clinics, DARPA, governance and risks.

$MEDSResearch updated November 5, 2026PDF · 21 pages

DataMeds AI: Terminated Control Proposal, Florida HMO and Financing

The terminated October control proposal, continuing licenses, conditional Florida HMO rollout, Corexa plans and June financial statements.

$MEDPResearch as of October 26, 2026PDF · 15 pages

Medpace: award quality, backlog conversion and cash discipline

Archived analysis of the full-service clinical-research model and the path from net awards to recognized revenue and collected cash. It examines cancellations, sponsor funding, backlog rules, operating leverage, lease obligations, repurchases, leadership and the interpretation of book-to-bill alongside the dated quarterly accounts.

$INOResearch updated November 6, 2026PDF · 53 pages

INOVIO: VOCERYQ Approval, Launch Economics and the November Financing

Accelerated approval of VOCERYQ on October 30, 2026, the RRP-001 evidence and the confirmatory requirement, the November 5 offering of about $75 million, preliminary September 30 cash of approximately $48.4 million with going-concern language, warrants, dilution, litigation and the wider pipeline.

$FATEResearch updated November 6, 2026PDF · 18 pages

Fate Therapeutics: third-quarter accounts, the CIRM grant and the FT819 lupus programme

Third-quarter 2026 operating expenses of $32.2 million, a net loss of $30.7 million and $139.1 million of cash and investments at September 30, with a guided runway into mid-2028 including the $15.0 million CIRM CLIN2 grant. FT819 in lupus nephritis, FT839 and the COMPLETE trial, the at-the-market programme, ownership and dilution are stated at their own dates.

$DRTSResearch as of October 26, 2026PDF · 23 pages

Alpha Tau Medical: Alpha DaRT, REGAIN, ReSTART and the funding test

A dated review of Alpha DaRT clinical programs and early evidence, ReSTART, REGAIN and IMPACT, the Tolmar relationship, cash and borrowing, shares and warrants, ownership and clinical-development risks.

$CERTResearch updated November 5, 2026PDF · 17 pages

Certara Stock Research: Q3 Results, Software Growth and 2026 Outlook

Q3 2026 continuing results, software and services mix, adjusted EBITDA definition, cash and term loan, share count, repurchase capacity and updated 2026 outlook.

$CAPRResearch as of October 26, 2026PDF · 60 pages

Capricor Therapeutics: Deramiocel, HOPE-3 and the FDA review

A dated review of deramiocel’s regulatory sequence, HOPE-3 and extension evidence, financial position and dilution, commercial-partner and legal risks, ownership, and the November FDA target and lease contingency.

$BDRXResearch as of October 26, 2026PDF · 12 pages

Biodexa: Serenta, bladder-cancer evidence and financing pressure

The archived research examines Serenta’s event-driven FAP study, the fully enrolled bladder-cancer trial and the limits of earlier efficacy observations. It separates sterling cash and operating consumption from dollar financing proceeds, and explains warrant terms, resale registration and the announced ADS-ratio change.

$AXSMResearch updated November 3, 2026PDF · 24 pages

Axsome Therapeutics: Q3 Earnings, AUVELITY and AXS-12

Q3 and nine-month results, commercial medicines, development milestones, cash flow, debt, dilution, governance and patent risks, with historical comparisons and a daily price chart through November 2, 2026.

$AUTLResearch as of October 26, 2026PDF · 12 pages

Autolus: AUCATZYL Manufacturing, Lupus Expansion and Credit Economics

Examines AUCATZYL’s launch funnel and manufacturing margins, the CARLYSLE lupus evidence, and how credit tranches, revenue-sharing payments and warrants affect the funding available for broader obe-cel development.

$ARCTResearch updated October 26, 2026PDF · 11 pages

Arcturus: OTC delivery, CF development and cash commitments

The September OTC results are examined through the small efficacy and safety populations, liver tolerability and the proposed transition to LUNAR 2.0. Cystic-fibrosis imaging and longer treatment, manufacturing services and the myNEO agreement add separate execution requirements. June cash, operating use, released CSL obligations, equity capacity and ownership explain the resources and commitments behind the next development cycle. The October 26 report label is distinct from the earlier visible news label.

$ALTResearch as of October 26, 2026PDF · 40 pages

Altimmune: Pemvidutide, MASH trials and the liver-disease pipeline

A dated review of pemvidutide across MASH, alcohol use disorder and alcohol-associated liver disease, covering IMPACT, PERFORMA, RECLAIM and RESTORE, the balance sheet, financing and dilution, clinical catalysts and development risks.

$ZVRAResearch updated November 4, 2026PDF · 19 pages

Zevra: Q3 Earnings, Commercial Cash, European Review and Celiprolol

Twelve analytical chapters plus falsifiers: commercial access and concentration, European review, NPC trial evidence and limitations, celiprolol and DiSCOVER, Q3 and nine-month financial statements, EPS and non-cash gains, operating cash, investments, debt repayment, taxes and rebates, dilution, ownership, insider transactions and risk scenarios. Daily price and volume chart with SMA 50/200 on page 2 through November 3, plus eight complete FAQ answers.

$VTRSResearch as of November 5, 2026PDF · 16 pages

Viatris: third-quarter accounts, the Pacira transaction and the December FDA date

Third-quarter 2026 revenue, the GAAP loss against adjusted EBITDA, operating cash flow and the raised guidance frame the financial position, with the Pacira tender and the December 27 meloxicam target date ahead. The presbyopia approval, the Nashik supply suspension, debt and capital allocation are stated at their own dates.

$SLNResearch as of October 24, 2026PDF · 12 pages

Silence: divesiran evidence and the next development stage

This report explains the SANRECO Phase 2 results and the remaining steps toward a later divesiran study. It examines clinical endpoints, enrollment, cash and the August financing alongside ADS mechanics, dilution and the difference between a successful readout and commercial value.

$SANAResearch updated November 6, 2026PDF · 13 pages

Sana Biotechnology: UP421 human evidence, SC451 timing and the September cash position

UP421 cell survival and function through 14 months in one recipient, set against SC451 as a separate stem-cell program, with the November 5 update keeping a 2026 trial start for SC451 and moving SG293 study initiation to the first quarter of 2027. Cash and marketable securities of $121.7 million at September 30, $108.9 million of nine-month operating cash use, a $20.4 million GAAP gain driven by $63.4 million of noncash fair-value benefits and a continuing going-concern warning frame the financing question.

$EPRXResearch as of October 24, 2026PDF · 18 pages

Eupraxia Pharmaceuticals: drug delivery and clinical data

The report examines Eupraxia’s drug-delivery platform, its clinical programs and the evidence needed to establish a durable therapeutic advantage. It follows study design, safety and regulatory milestones alongside June liquidity, cash use and the funding implications of later development.

$CMPXResearch updated November 6, 2026PDF · 16 pages

Compass Therapeutics: tovecimig endpoints and the survival-evidence gap

COMPANION-002’s response and progression findings are examined beside its non-significant survival result and FDA feedback. The report distinguishes crossover analyses, safety, early antibody programs, June resources and the financing implications of additional clinical evidence.

$BLLNResearch updated November 5, 2026PDF · 19 pages

BLLN Stock Research: Q3 Results, 2026 Guidance and Northstar Clear

Q3 results, higher 2026 revenue guidance, Northstar Clear, cash generation, Oberland debt and dual-class equity.

$ZNTLResearch as of October 23, 2026PDF · 15 pages

Zentalis: azenosertib survival evidence, DENALI and the financing bridge

Examines the WEE1 and Cyclin E1 hypothesis through DENALI’s response populations, survival follow-up, dose selection and safety, while separating single-arm findings from randomized ASPENOVA evidence. June financial resources are connected to the completed August offering, runway guidance, share count and licensing economics. Diagnostic deployment, treatment competition and the risks of translating selected clinical activity into an approved product complete the analysis.

$ZLABResearch as of November 5, 2026PDF · 15 pages

Zai Lab: third-quarter accounts, the October placement and the povetacicept target

Third-quarter 2026 revenue of $108.2 million, a net loss of $46.1 million and $659.7 million of cash, restricted cash and short-term investments at September 30, plus about $241.2 million net from the October private placement. The Vertex povetacicept FDA target, zoci in small cell lung cancer and neuroendocrine carcinomas, ZL-1503 and the regional rights that separate partner sales from Zai Lab revenue are stated at their own dates.

$VRTXResearch updated November 4, 2026PDF · 20 pages

Vertex: Q3 Earnings, Crinetics Accounting and Renal Catalysts

All 15 original chapters: Q3 and nine-month finances, purchase accounting, commercial launches, renal and endocrine evidence, cell therapy, capital structure, risks and historical comparisons. Daily price chart through November 3, after the Q3 release.

$VCREResearch updated November 5, 2026PDF · 21 pages

Vicore Pharma: ASPIRE’s randomized test, IPF evidence and ADS claims

Sets buloxibutid’s uncontrolled AIR findings against the randomized ASPIRE Phase 2b design and the increasingly demanding treatment benchmarks in idiopathic pulmonary fibrosis. The discussion explains observed versus imputed lung-function results, safety, patent protection and the Japan partnership rather than treating an early signal as confirmed efficacy. The Q3 2026 interim report of November 5 showed SEK 772.0 million at September 30 and runway guidance into H2 2028. Swedish-krona financials, operating cash use, runway assumptions and dilution are paired with the mechanics of the Nasdaq ADS listing, which itself raised no new capital.

$TNGXResearch as of October 23, 2026PDF · 17 pages

Tango Therapeutics: PRMT5, pancreatic cancer and the development test

Archived research on the MTAP-deletion rationale, vopimetostat monotherapy and the early RAS-combination cohorts, with attention to evaluable-patient denominators, safety and durability. The report examines the randomized-development path, June financial resources, capital structure and the economics of partner-dependent combinations. Original clinical and market reference dates are retained.

$IVAResearch as of October 23, 2026PDF · 24 pages

Inventiva: NATiV3, Lanifibranor and the Warrant Dilution Map

Lanifibranor’s Phase 2b foundation and NATiV3’s biopsy endpoints, cohort definitions and readout framework. The financing analysis tracks EIB refinancing, secured debt and warrant triggers that link clinical timing to cash needs and potential dilution.

$IRONResearch updated November 6, 2026PDF · 17 pages

Disc Medicine: third-quarter accounts, the APOLLO topline and the bitopertin resubmission

Third-quarter 2026 research and development expense of $44.1 million, a net loss of $59.5 million and $682.8 million of cash and securities at September 30, plus about $486 million net from the October offering and a guided runway into 2030. The APOLLO topline, the planned NDA resubmission, selcodebart, DISC-3405, Hercules debt and licensed assets are stated at their own dates.

$IONSResearch as of October 23, 2026PDF · 15 pages

Ionis: Hibsago royalties, commercial launches and financial claims

Connects Hibsago’s hepatitis-B evidence and approved population with GSK royalty terms, geographic rights and launch execution. Owned TRYNGOLZA, DAWNZERA and ZANVASTRO opportunities sit alongside European review, neurological and kidney programs, and the negative cardiovascular evidence. June revenue, cash consumption, convertible debt and royalty financing explain why approval and headline product sales differ from durable income retained by Ionis shareholders.

$FDMTResearch as of October 23, 2026PDF · 15 pages

4D Molecular Therapeutics: genetic medicines and clinical data

The report examines 4D Molecular Therapeutics’ engineered-vector platform, principal clinical programs and the clinical endpoints that matter for development decisions. It follows tolerability, durability, manufacturing and regulatory execution together with cash consumption, financing and dilution risks.

$ELTXResearch updated November 6, 2026PDF · 15 pages

Elicio: AMPLIFY evidence, lymph-node targeting and the financing of future studies

Separates the randomized AMPLIFY-7P primary-endpoint miss from immune responses, nominal subgroups and exploratory adjusted analyses. The report compares the 7P strategy with earlier AMPLIFY-201 observations and examines the requirements for prospective combinations or a refined development population. Intellectual property, manufacturing, secured obligations, June cash consumption, July financing and potential dilution determine the resources and ownership cost of advancing ELI-002 after the clinical setback.

$CRBPResearch as of October 23, 2026PDF · 15 pages

Corbus: ADC evidence, obesity tolerability and the financing path

CRB-701’s Nectin-4 ADC design is followed through indication-specific tumor responses, evaluable populations, ocular toxicity and the randomized TEMPO-1 strategy. CRB-913’s peripheral CB1 mechanism and CANYON-1 weight-loss signal are examined alongside psychiatric tolerability, dose exposure and chronic-treatment requirements. Licensing territories, milestones, royalties, historical cash use, financing capacity and potential dilution connect the two clinical programs with the resources and retained economics needed to reach larger studies.

$BLSMResearch as of October 23, 2026PDF · 15 pages

BlossomHill Therapeutics: precision oncology and pipeline

The report examines BlossomHill’s precision-oncology candidates, target selection and the clinical evidence needed to establish a useful treatment profile. It follows the post-IPO capital structure, June financial statements, development expenditure and the uncertainty between early programs and a commercial franchise.

$ABUSResearch as of October 23, 2026PDF · 17 pages

Arbutus: HBV development, settlement economics and the tender

The archived report separates AB-101 and imdusiran clinical development from intellectual-property recoveries and Genevant economics. It traces the Moderna settlement receipt, conditional litigation paths, the completed 46 million-share tender, June cash flow and the gap before a reported post-tender balance sheet.

$VRCAResearch as of October 22, 2026PDF · 14 pages

Verrica Pharmaceuticals: ycanth and clinical development

The report examines YCANTH’s commercial performance, the COVE-2 common-warts study and the separate VP-315 development program. It follows June liquidity, secured borrowing conditions and the difference between product dispensing, recognized revenue and cash available to fund further clinical work.

$SGMTResearch as of October 22, 2026PDF · 15 pages

Sagimet Biosciences: denifanstat and aurora

The report examines FASN inhibition in acne, the partner studies in China and the design and clinical questions facing the U.S. AURORA program. It follows adolescent development, tolerability, retained rights and the distinction between June financial resources, October financing and later runway guidance.

$SCYXResearch updated November 5, 2026PDF · 18 pages

SCYNEXIS: third-quarter accounts, SCY-770 and the BARDA-backed antifungal

Third-quarter 2026 revenue, cash use and the shelf registration frame the funding position, with the Form 10-Q stating at least twelve months of resources. SCY-770 in ADPKD and oral and intravenous SCY-247 are assessed against the BARDA base period and its conditional options, alongside BREXAFEMME economics, warrants and dilution.

$RNXTResearch as of October 22, 2026PDF · 13 pages

RenovoRx: device adoption, survival evidence and funding conditions

Separates RenovoCath device commercialization from the investigational drug-delivery combination being tested in TIGeR-PaC. Early pancreatic-cancer observations and trial milestones are assessed without substituting uncontrolled findings for the randomized survival result. The report then follows device sales, operating expenditure, cash and runway assumptions, outstanding shares, warrants and financing capacity, connecting the clinical timetable with the commercial and capital needs that could change the company’s position before definitive evidence arrives.

$NNVCResearch as of October 22, 2026PDF · 18 pages

NanoViricides: antiviral evidence, program rights and financial continuity

NV-387’s Ebola exploratory run-in and planned controlled stage are distinguished from the separate mpox program and animal toxicology. Study design, dosing, safety interpretation and regulatory designations frame what patient evidence must establish. The fiscal-year cash bridge, subsequent financing, related-party credit, program rights, warrants and ATM restrictions explain why clinical progress and financial continuity must be evaluated together rather than treating permission or capacity as efficacy or cash.

$MBRXResearch as of October 22, 2026PDF · 15 pages

Moleculin: MIRACLE interpretation, financing and the post-split capital structure

MIRACLE’s first randomized unblinding, prior-treatment subgroups and cardiac-safety observations are examined without substituting blinded updates for the complete analysis. Trial design and dose selection frame the Annamycin program alongside the broader pipeline. The completed August financing, warrants, ATM use, dated cash-flow bridge and October reverse split show the funding trade-offs, while listing uncertainty and trial execution remain explicit risks.

$IMVTResearch as of October 22, 2026PDF · 16 pages

Immunovant: FcRn evidence, RA trial design and licensed economics

Examines imeroprubart’s FcRn mechanism and the distinction between antibody reduction and disease-specific clinical benefit, including open-label rheumatoid-arthritis responses and the randomized maintenance test. The CLE failure, batoclimab discontinuation and competitor Sjogren setback frame the remaining Graves, myasthenia-gravis and later programs. June cash, operating spending, HanAll license obligations and Roivant control connect clinical opportunity with funding and per-share risk. Review label: October 22; market and assessment dates remain distinct.

$DMACResearch as of October 22, 2026PDF · 14 pages

DiaMedica Therapeutics: dm199 and clinical development

The report examines DM199, its proposed biology and the clinical evidence in vascular and neurological indications. It distinguishes trial milestones from treatment benefit, and follows manufacturing, regulatory execution, historical cash resources and the assumptions behind further funding needs.

$CYTKResearch updated November 5, 2026PDF · 20 pages

CYTK Stock Research: MYQORZO Sales, MAPLE and Non-Obstructive HCM

Q3 results, MYQORZO launch, the MAPLE label review, the separate non-obstructive HCM plans, cash flows and financing.

$CGTXResearch updated November 5, 2026PDF · 22 pages

Cognition Therapeutics: Q3 Cash, DLB Planning and Nasdaq Compliance

Q3 statements, Nasdaq bid-price compliance, zervimesine development and capital structure.

$VRDNResearch updated November 4, 2026PDF · 22 pages

Viridian: First Lumvoa Revenue, Q3 Cash Flow and the Subcutaneous Pipeline

All twenty-two analytical chapters and three original historical figures: approval and label, TED biology, Lumvoa uptake and payer access, elegrobart trials and the March REVEAL reaction, FcRn/TSHR pipeline, complete Q3 accounts and derived quarterly cash flow, revenue recognition, convertible debt, DRI royalties, preferred shares, awards, ownership, management, manufacturing, competition and dated scenarios. Daily price/volume chart with SMA 50/200 on page 2, five-pillar Health Score, six historical analytical answers and eight complete current FAQs.

$UNCYResearch as of October 21, 2026PDF · 15 pages

Unicycive: OLC vendor remediation, the FDA review and warrant claims

Follows OLC’s two complete response letters, second-vendor resubmission and accepted FDA review, separating manufacturing compliance from clinical tolerability and commercial adoption. The clinical discussion preserves the treated and evaluable populations behind phosphate-control and pill-burden claims. June cash, operating use, runway guidance, two securities actions, pre-funded instruments and milestone-linked warrant expirations show how regulatory progress interacts with funding needs and substantial potential dilution.

$TRDAResearch as of November 5, 2026PDF · 18 pages

Entrada Therapeutics: third-quarter cash and four readouts through H1 2027

Third-quarter 2026 cash, spending and the runway the company now extends into Q4 2027 frame the funding position, with four clinical readouts scheduled through the first half of 2027. The intracellular-delivery platform, the ELEVATE-44 and ELEVATE-45 cohorts, the Vertex-partnered VX-670 programme and the share count are stated at their own dates.

$TRAXResearch updated November 4, 2026PDF · 20 pages

First Tracks: Q3 Financials, ANB033 Healing and October Financing

All fifteen analytical chapters: CD122 biology, controlled gluten-challenge data, distinct mucosal-healing test, safety and statistical limits, earlier IL-15 trials, EoE and planned expansion, rosnilimab and ANB101, Q3 financials and historical comparisons, separation accounting, cash flow, placement and resale terms, awards, ownership, management and competing treatments. Daily price and volume chart with SMA 50 on page 2; fewer than 200 post-listing sessions are available for SMA 200. Includes eight complete current FAQ answers and earlier dated clinical questions.

$TGTXResearch as of October 21, 2026PDF · 17 pages

TG Therapeutics: BRIUMVI Sales, Subcutaneous Development and Blue Owl Debt

BRIUMVI’s commercial ramp, ULTIMATE evidence and subcutaneous development are set against the economics of the Blue Owl loan. The report also examines buybacks, launch spending and competition within the anti-CD20 market. Date label: October 21; includes October 23 updates.

$SVRAResearch as of October 21, 2026PDF · 36 pages

Savara: MOLBREEVI, IMPALA-2 and Conditional Debt

MOLBREEVI’s regulatory sequence and IMPALA-2 endpoints, with close attention to manufacturing questions and the limits of the reported evidence. Conditional borrowing, royalty obligations and outstanding warrants explain how development outcomes change Savara’s financing position.

$STIMResearch updated November 4, 2026PDF · 21 pages

Neuronetics: third-quarter results, cash and the going-concern disclosure

Dated research on Neuronetics after the third-quarter 2026 results and the November 4, 2026 Form 10-Q: NeuroStar and Greenbrook revenue, gross margin, positive adjusted EBITDA alongside GAAP losses and interest expense, 2026 revenue guidance of $160–164 million, cash, debt covenants, ATM issuance and the going-concern disclosure. Daily price chart through the November 3, 2026 close.

$MSLEResearch as of October 21, 2026PDF · 14 pages

Satellos: BASECAMP evidence, muscle regeneration and funding

Explores forazapadin's muscle-regeneration rationale through the controlled pediatric BASECAMP study, four-adult TRAILHEAD observations and the planned FSHD program. Enrollment, delayed result guidance, biomarker changes and functional measures are separated from proof of clinical benefit. June cash and investment balances, rising development expenditure, conditional foundation funding, pre-funded warrants and the ATM program frame the financing and dilution risks surrounding the next clinical milestones.

$GRALResearch updated November 5, 2026PDF · 20 pages

GRAL Stock Research: GRAIL Q3 Results and Galleri FDA Review

Q3 financial results, Galleri clinical evidence, the FDA advisory votes, liquidity and dilution.

$FULCResearch as of October 21, 2026PDF · 11 pages

Fulcrum: proposed transaction, distribution and residual value

This archive explains the proposed cash distribution and retained interest in a new migraine company, including the conditions that must precede closing. It assesses historical resources, development setbacks, transaction mechanics and the difference between announced per-share illustrations and a completed payment.

$BCDAResearch as of October 21, 2026PDF · 18 pages

BioCardia: Helix, the CardiAMP Japan route and a narrow equity cushion

BioCardia’s Helix feedback package and CardiAMP Japan submission plans meet a narrow equity cushion and an exhausted June ATM. The report examines trial limitations, confirmatory enrollment, cash runway, warrants and financing scenarios.

$BBOTResearch as of October 21, 2026PDF · 16 pages

BridgeBio Oncology: RAS combinations, early trials and dilution

Maps BBO-8520, BBO-11818 and BBO-10203 across RAS and PI3Kα biology, focusing on the logic of internal combinations and the limits of small Phase 1 datasets. Early response evidence is considered alongside dose finding, safety, durability and the distinction between monotherapy and combination updates. Financial chapters trace liquidity, development spending, runway guidance, the public-market structure, resale overhang and equity dilution, showing how funding supports experimentation without removing shared biological risk.

$ANABResearch as of October 21, 2026PDF · 15 pages

AnaptysBio: retained royalties, Sagard thresholds and partner dependence

Research on the royalty company after the First Tracks separation, with a detailed distinction between retained Quimilza royalties and transferred milestone rights. It examines Jemperli clinical expansion, contractual litigation, Sagard receipt thresholds, the GEMINI evidence and the difference between tax-driven accounting profit and distributable cash.

$VTGNResearch as of October 20, 2026PDF · 14 pages

Vistagen: Fasedienol’s PALISADE Record, Trial Redesign and the Nasdaq Deadline

Contrasts fasedienol’s four PALISADE trials and the limits of open-label and subgroup analyses, then examines how cash consumption, financing needs and the Nasdaq bid-price deadline constrain another controlled trial.

$SPROResearch as of October 20, 2026PDF · 18 pages

Spero: Utebzi economics, licensing and runway

The archive follows Utebzi from approval toward availability and examines the separate SP001 licensing arrangement. It explains royalties, partner obligations, cash resources and financing capacity, distinguishing management’s funding horizon from cash already received and future commercial execution.

$PACBResearch updated November 5, 2026PDF · 23 pages

PACB Stock Research: Q3 Results, HiFi Adoption and CFO Transition

Q3 results, narrower revenue guidance, HiFi sequencing adoption, cash and convertibles, and the CFO transition.

$OSCRResearch updated November 5, 2026PDF · 18 pages

Oscar Health: Q3 Underwriting, Cash Flows and 2027 Enrollment

Q3 earnings, medical costs and reserves, raised 2026 outlook, parent liquidity and the enrollment calendar.

$ONCYResearch as of October 20, 2026PDF · 15 pages

Oncolytics: Pelareorep, REO 033 Colorectal Evidence and ATM Financing

Compares pelareorep’s colorectal and GOBLET evidence, separates randomized comparisons from small response cohorts, and explains how evaluable-patient timing, a limited cash reserve and ATM share sales interact in the development plan. News label: October 20; includes the October 27 GOBLET update.

$MDGLResearch updated November 4, 2026PDF · 20 pages

Madrigal: Rezdiffra Profitability, Cash Conversion and Cirrhosis Outcomes

All twenty analytical chapters: approved indication, pivotal evidence, outcomes trials, adoption, Q3 earnings and cash flows, historical financials, debt, equity and EPS, combinations, RNA programs, manufacturing, competition, governance, valuation and risks. Daily price chart on page 2 through November 3, after Q3.

$MANEResearch as of October 20, 2026PDF · 15 pages

Veradermics: hair-growth evidence and the clinical pathway

The report examines Veradermics’ hair-growth studies and how endpoints, treatment duration and safety shape the development case. It connects the reported clinical observations with financial resources, competition and capital requirements, distinguishing an encouraging dataset from completed registration and commercial uptake.

$LPCNResearch as of November 5, 2026PDF · 14 pages

Lipocine: third-quarter accounts, the BLOOM study and the cash position

Third-quarter 2026 revenue of $2.3 million, a net loss of $0.7 million and $21.5 million of unrestricted cash and investments at September 30, about $28.5 million at November 4. The BLOOM Phase 3 in postpartum depression, the prior Phase 3 result, TLANDO royalties, equity capacity and ownership are stated at their own dates.

$IBIOResearch as of October 20, 2026PDF · 12 pages

iBio: obesity antibody translation, fiscal runway and pre-funded ownership

The report traces iBio’s obesity antibodies from target biology and animal body-composition observations to early human dosing and planned clinical windows. It distinguishes target inhibition, the composition of lost mass and potential patient benefit, while examining the different stages of IBIO-600, IBIO-610 and IBIO-800. Fiscal cash use, runway assumptions, licenses, ordinary and pre-funded warrants, incentive reserves and the completed October capital vote show how development progress interacts with ownership and financing.

$GPCRResearch as of October 20, 2026PDF · 16 pages

Structure Therapeutics: aleniglipron evidence, oral amylin and capital

Distinguishes aleniglipron’s pivotal program from the separate body-composition, diabetes and treatment-switch studies, then considers ACCESS extension findings and the earlier-stage oral amylin opportunity. Clinical maturity, follow-up and safety are weighed against competition in obesity rather than merged into a single efficacy claim. The financing analysis covers cash and investments, research spending, ADS mechanics, warrants and issuance capacity; the original Health assessment remains qualitative, with no numerical composite score.

$DCOYResearch as of October 20, 2026PDF · 16 pages

Decoy: designable antivirals, restricted cash and the warrant stack

The archived report examines peptide-based antiviral design, tissue-exposure findings and the difference between cell or animal observations and human efficacy. It follows the proposed Animal Rule route, respiratory development, restricted grant cash, September warrant inducement, the resale registration and financing needs before planned clinical entry.

$SYREResearch updated November 4, 2026PDF · 28 pages

Spyre Therapeutics: Q3 Financials, SKYWAY, SKYLINE and HS

All twenty-five analytical chapters and the falsification framework: antibody platform and licensing, three SKYLINE Part A cohorts, randomized Part B design, detailed SKYWAY results, SPY772 and SKYLIGHT, Q3 and nine-month financials, cash flows, preferred stock, completed warrant exercises, ATM and offering terms, ownership, management, market structure and risks. All five dated scientific and financial figures, daily price and volume chart with SMA 50/200 on page 2 through November 3, and eight complete FAQ answers.

$RAREResearch updated November 4, 2026PDF · 20 pages

Ultragenyx: Q3 Accounts, Royalty Obligations and Voucher Proceeds

All eight analytical chapters, approved therapies and clinical setbacks, Q3 and historical financials, full cash flow, September royalty roll-forward, shares and exercised warrants, voucher gross and net proceeds, restructuring, ownership and dated catalyst requirements. Daily candles, volume, SMA 50 and SMA 200 on page 2; eight current FAQ answers.

$CRMDResearch as of October 19, 2026PDF · 13 pages

CorMedix: DefenCath Reimbursement, REZZAYO Prophylaxis and Cash Collateral

Connects DefenCath’s post-TDAPA pricing reset with the ReSPECT prophylaxis evidence for REZZAYO, showing why customer rebates, collateral requirements and acquisition-related obligations matter even when reported earnings and operating cash flow are positive.

$CGEMResearch as of October 19, 2026PDF · 18 pages

Cullinan: autoimmune T-cell engagers, zipalertinib and conditional economics

Research distinguishes the early autoimmune evidence for CLN-978 and velinotamig from CLN-049 leukemia development and zipalertinib’s regulatory applications. It examines dose and safety limits, the REZILIENT3 comparison, Taiho partnership economics, June liquidity, dilution and the separate November, December and FDA decision windows.

$BLTEResearch as of October 19, 2026PDF · 14 pages

Belite Bio: retinal evidence, trial design and funding

This report explains the retinal-disease development program, its clinical endpoints and the distinction between interim evidence and a registrational outcome. Financial resources, spending, competitive approaches and potential dilution are considered alongside the milestones that would change the evidence base.

$LRMRResearch as of October 17, 2026PDF · 15 pages

Larimar: frataxin replacement, surrogate approval and the cost of confirmation

Examines nomlabofusp’s mitochondrial protein-replacement thesis and the use of skin frataxin as a proposed surrogate for accelerated approval. Open-label biomarker and functional groups, external natural-history comparisons, exposure and anaphylaxis are assessed separately from randomized confirmation. The rolling application, manufacturing and registry timelines are connected to launch preparation, cash runway, preferred conversion, options and the potential financing needed beyond the initial regulatory window.

$ABVXResearch as of October 17, 2026PDF · 14 pages

Abivax: Obefazimod, ABTECT Maintenance and the Royalty Buyback

Obefazimod’s ABTECT induction and maintenance evidence, with responder selection, dosing, safety and NDA preparation. June liquidity, July equity proceeds and the buyback of royalty certificates show how clinical spending and financing affect cash and shareholder dilution.

$RCKTResearch as of October 16, 2026PDF · 15 pages

Rocket Pharmaceuticals: the Danon restart, Kresladi and the funding bridge

RP-A501’s revised Danon trial must pair durable responses with acceptable safety. This report examines its pivotal design, Kresladi commercialization, voucher-funded June liquidity, conditional Hercules borrowing, ongoing cash consumption and the instruments affecting per-share exposure.

$EDSAResearch as of October 16, 2026PDF · 17 pages

Edesa: EB06 trial design, inflammatory-disease evidence and financing

EB06’s anti-CXCL10 rationale is connected to the placebo-controlled vitiligo design, facial endpoint, recruitment sequence and limits of earlier exposure data. Paridiprubart respiratory results and exploratory kidney-injury analyses are distinguished from prospective confirmation, with daniluromer adding a separate development option. Historical cash, the August offering, warrants, licensing obligations and preferred instruments frame the funding and dilution needed to produce controlled evidence. Report label: October 16; an October 23 compensation update is preserved separately.

$AMLXResearch updated November 5, 2026PDF · 27 pages

Amylyx: Q3 Results, Avexitide Filing and the LUCIDITY Program

Q3 results, financing and runway, LUCIDITY and the avexitide filing timeline.

$XBIOResearch as of October 15, 2026PDF · 14 pages

Xenetic: DNase translational evidence and Santersus ownership mechanics

Archived research examines the DNase and neutrophil-extracellular-trap hypothesis, CAR T translational work and the first small investigator-initiated lymphoma study. It separates Santersus NucleoCapture programs from Xenetic’s current assets and traces transaction conditions, illustrative issuance, royalty support, standalone cash and related-party risks.

$ADMAResearch updated November 5, 2026PDF · 18 pages

ADMA Stock Research: Q3 Results, ASCENIV Growth and SG-001

Q3 results, ASCENIV and BIVIGAM trends, updated guidance, cash flow, repurchases and SG-001 development.

$MISTResearch as of October 13, 2026PDF · 17 pages

Milestone Pharmaceuticals: CARDAMYST Uptake, ReVeRA-301 and Royalty Financing

Looks beyond CARDAMYST’s covered-lives statistics to reimbursed prescriptions and collected sales, while separating ReVeRA-301’s AFib-RVR development from the PSVT franchise and tracing the claims created by convertible notes and royalty financing. Research label: October 13; includes October 19 and 28 updates.

$BMEAResearch as of October 13, 2026PDF · 17 pages

Biomea Fusion: BMF-650, icovamenib and the financing deadline

BMF-650’s outpatient weight-loss findings and confined-cohort limitations are examined alongside icovamenib’s diabetes studies, the menin hypothesis, historical cash consumption, the going-concern warning, cancelled financing, potential dilution and the December warrant expiry.

$TYRAResearch as of October 12, 2026PDF · 16 pages

Tyra: pediatric growth evidence and the funding base

This archive explains dabogratinib’s pediatric sentinel dataset, the larger BEACH301 study and the revised timing for initial results. It examines height-velocity limitations, competing oral therapy, the oncology program and financing, including common shares and pre-funded equivalents.

$TENXResearch updated November 6, 2026PDF · 18 pages

Tenax: third-quarter cash, the LEVEL-2 amendment and the FDA Type C meeting

Third-quarter 2026 cash, spending and the company-stated runway through fiscal 2028 frame the funding position, with the FDA Type C meeting granted and LEVEL-2 enrollment paused while the protocol is amended. LEVEL results, the enrichment criteria, warrant exposure and the share count are stated at their own dates.

$QTTBResearch updated November 4, 2026PDF · 24 pages

Q32 Bio: Q3 Funding, Share Claims and the Bempikibart Pivotal Path

All twenty-one analytical chapters, five historical questions and two original historical figures, covering IL-7/TSLP biology, SIGNAL-AA Part B, mITT/ITT and off-drug denominators, EADV evidence, competition, clinical design, complete Q3/9M accounts and cash flow, July financing, actual shares and pre-funded equivalents, ATM utilization, asset-sale receipts, contingent milestones, ownership and scenarios. Daily price/volume chart with SMA 50/200 on page 2, five-pillar Health Score and eight complete current FAQ answers.

$QNTMResearch as of October 12, 2026PDF · 15 pages

Quantum BioPharma: Lucid-MS, Unbuzzd and capital allocation

This report separates Lucid-MS clinical clearance from proof of efficacy and Unbuzzd’s proposed listing from a completed transaction. It examines cash, digital assets, ownership and financing alongside litigation, spending and the evidence needed to sustain development.

$PMVPResearch as of October 12, 2026PDF · 12 pages

PMV Pharmaceuticals: ovarian response evidence and the warrant reset

Examines rezatapopt’s ovarian-cancer response evidence, including confirmation, durability, safety and the limits of the PYNNACLE populations. June resources and operating cash use are reconciled with the September financing, management’s runway plan, pre-funded warrants and common-warrant adjustments tied to FDA acceptance. Clinical development, commercial preparation and ownership complete the discussion of regulatory uncertainty and dilution. Report label: October 12; underlying review attribute: September 23.

$PLXResearch as of October 12, 2026PDF · 14 pages

Protalix: Elfabrio Partner Terms, PRX-115 and Working Capital

Elfabrio’s partner economics, Elelyso sales and the PRX-115 gout program define Protalix’s business mix. Inventory, receivables, milestone income and equity financing are examined to explain the difference between accounting profit and cash available for development.

$PCVXResearch updated November 5, 2026PDF · 19 pages

Vaxcyte: VAX-31, OPUS evidence, Q3 2026 results and financing

Dated research on Vaxcyte after its third-quarter 2026 results of November 4, 2026: the VAX-31 OPUS-1 pivotal adult results and serotype-level comparisons, the fully enrolled OPUS-2 and OPUS-3 trials and the infant calendar, VAX-A1, cash, cash equivalents and investments of $2,264.4 million at September 30 before approximately $1.1 billion of October net proceeds, the equity and convertible-note financing, dilution and the Health Score. Daily price chart through the November 4, 2026 close.

$APMDResearch as of October 12, 2026PDF · 17 pages

Apnimed: AD109 evidence, FDA meaningfulness and the cost of launch

Examines the completed SynAIRgy and LunAIRo trials through patient populations, airway measurements, estimands, reported symptoms and treatment persistence. FDA questions about clinical meaningfulness and adverse-event discontinuation frame the pending AD109 application, rather than an assumed approval. June cash, the subsequent IPO, conditional credit tranches, revenue participation, Shionogi economics and prospective dilution connect the oral-treatment opportunity with the resources and obligations needed for launch.

$AGENResearch updated November 5, 2026PDF · 20 pages

Agenus: Q3 Results, BOT+BAL Access and ROBBIN

Q3 results, noncash royalties, BOT+BAL access and the Phase 3 ROBBIN development plan.

$XRTXResearch as of October 10, 2026PDF · 14 pages

XORTX: XORLO evidence, regulatory plans and financing risk

Examines XORLO's formulation and pharmacokinetic history, the proposed XRx-026 gout study and the separate US IND and Canadian CTA pathways. The discussion distinguishes development preparation from authorization, clinical efficacy and a later funding-dependent NDA ambition. June cash, working capital, prepaid services and conflicting historical cash-flow presentations are assessed alongside offering proceeds, investor-relations commitments, pre-funded warrants, reverse splits and the larger economic share base behind the small common-share count.

$COGTResearch updated November 6, 2026PDF · 15 pages

Cogent: bezuclastinib, third-quarter results and regulatory steps

The report follows bezuclastinib across clinical populations and regulatory milestones, with attention to study design and safety. It adds the third-quarter 2026 results — $791.1 million of cash and securities at September 30, a $111.4 million net loss and funding into late 2028 — and assesses spending, capital structure and commercialization requirements while distinguishing strong trial results from completed approval or future sales.

$ALMSResearch as of October 9, 2026PDF · 14 pages

Alumis: separate psoriasis and lupus evidence, resources and dilution

Envudeucitinib’s positive psoriasis studies are separated from the overall LUMUS lupus failure and its prespecified interferon-signature subgroup hypothesis. The report examines BICLA, endpoint hierarchy, subgroup denominators, safety and the regulatory requirements for an enriched development path. ONWARD durability, A-005, Kaken’s Japan rights, cash composition, operating use, equity financing and dilution connect the clinical evidence with the capital needed for potential filings, trials and commercialization.

$BFRIResearch as of October 8, 2026PDF · 14 pages

Biofrontera: Ameluz label expansion, treatment economics and capital needs

Examines Ameluz’s drug-and-lamp photodynamic therapy platform, the approved superficial basal-cell indication and the separate submitted actinic-keratosis expansion. The planned launch window is weighed against reimbursement, adoption, lamp supply, legal and patent conditions and orders brought forward before potential restrictions. Revenue growth and gross-margin improvement are separated from operating losses, limited cash, going-concern doubt, expected milestones and share dilution, preserving the dates of each commercial and financial claim. Latest written news review: October 8.

$CINGResearch as of October 4, 2026PDF · 16 pages

Cingulate: CTx-1301, CMC Remediation and Launch Funding

CTx-1301’s release technology, clinical evidence and manufacturing remediation after the FDA response letter. The report examines launch infrastructure, cash consumption and potential equity issuance without treating a resubmission plan as a dated regulatory decision.

$CANFResearch as of October 4, 2026PDF · 18 pages

Can-Fite BioPharma: namodenoson and piclidenoson

The report examines the blinded LIVERATION survival observation, the pivotal psoriasis program and the exploratory pancreatic-cancer evidence without combining their different designs. It follows the A3 adenosine-receptor platform, June financial resources, September warrant financing and the potential ownership changes from repeated funding.

$SCTXResearch as of October 2, 2026PDF · 19 pages

Scribe: epigenetic silencing, first-human evidence and IPO economics

The archived report examines STX-1150’s PCSK9 silencing approach and distinguishes the first-human study from preclinical cardiovascular evidence. It follows the STX-1200 and STX-1400 pipeline, CIRM support, partner rights, July IPO and note conversion, pro forma liquidity, lock-up timing and the evidence required for durable LDL-C lowering.

$CLDXResearch updated November 6, 2026PDF · 17 pages

Celldex: Third-Quarter Cash, the 2027 BLA Path and Barzolvolimab Safety

Third-quarter 2026 results: $650.3 million of cash and securities at September 30, $65.0 million of quarterly operating cash use, a $75.6 million net loss and funding guidance through 2028. EMBARQ-CSU evidence, anaphylaxis risk, the planned 2027 BLA, the new November shelf and the dilution channels.

$ATTOResearch as of October 2, 2026PDF · 11 pages

Attovia: chronic-pruritus evidence, ATTO-2306 and IPO funding

Archived research separates healthy-volunteer findings from initial chronic-pruritus patient observations and the planned complete Phase 1 b dataset. It examines ATTO-1310 and ATTO-2306, the competitive immunology setting, June cash use, the completed August IPO, option dilution and the planned transition to Phase 2.

$ACIUResearch updated November 4, 2026PDF · 27 pages

AC Immune: Q3 Resources, VacSYn Evidence and the Updated Clinical Windows

All sixteen analytical chapters, seven historical questions and five original historical financial figures, covering VacSYn design and week-100 evidence, antibody responses versus clinical efficacy, ACI-19764, owned and partnered programs, Q3/9M IFRS results, resources and deferred revenue, complete dated H1 cash flows, share/treasury/ATM context, governance and scenarios. Daily price/volume chart with SMA 50/200 on page 2, reassessed five-pillar Health Score and eight complete current FAQ answers.

$ALDXResearch updated September 30, 2026PDF · 16 pages

Aldeyra Therapeutics: the reproxalap appeal, cash runway and the next NDA steps

Aldeyra’s planned formal appeal of the reproxalap CRL is distinct from a subsequent NDA resubmission or approval. The report examines the evidence dispute, ADX-2191, AbbVie optionality, June cash, operational runway and future dilution. News label: September 30; Health Score assessed October 4.

$SLSSnapshot as of September 3, 2026PDF · 12 pages

SELLAS Life Sciences: expanded sentiment snapshot ahead of the REGAL 80th event

Expanded cross-platform sentiment snapshot from September 3, 2026: social-platform score and the bullish/bearish tagged split, dedicated-forum conviction, long-form investor debate, news flow and short positioning, read against the price move from the late-August peak. Reference price $13.79, REGAL status at 78 of 80 events. A dated observation, not a recommendation.

A biotech research index, not just a calendar

This page is the central Merlintrader index for company-level biotech research. It connects readers to analysis of pipelines, lead assets, FDA catalysts, clinical evidence, cash runway, dilution risk, management execution and market context. Unlike a simple catalyst calendar, this page helps you move from a date or headline to the deeper company questions that matter: what the asset does, what the next catalyst is, how strong the balance sheet looks and what risks could change the setup.

XBI sector reference chart

XBI biotech sector proxy chart from Finviz

Daily chart of the SPDR S&P Biotech ETF (XBI), a common reference for the sector. Affiliate link.

Browse biotech stock hubs

Every company in our biotech coverage has a stock hub with the current situation: latest news, key data, the next catalyst and the risks. Search by ticker or company name.

Open the biotech stock hub directory (238 companies)
$ABCL AbCellera Biologics$ABEO Abeona Therapeutics$ABUS Arbutus Biopharma Corporation$ABVX Abivax SA$ACIU AC Immune$ADCT ADC Therapeutics$ADMA ADMA Biologics$AGEN Agenus Inc.$AGIO Agios Pharmaceuticals$AKBA Akebia Therapeutics$ALDX Aldeyra Therapeutics$ALLO Allogene Therapeutics$ALMS Alumis$ALNY Alnylam Pharmaceuticals$ALT Altimmune$AMLX Amylyx Pharmaceuticals$AMRN Amarin Corporation$AMRX Amneal Pharmaceuticals$ANAB AnaptysBio$ANL Adlai Nortye$ANNX Annexon$APMD Apnimed$AQST Aquestive Therapeutics$ARCT Arcturus Therapeutics$ARDX Ardelyx$ARQT Arcutis Biotherapeutics$ARTL Artelo Biosciences$ARTV Artiva Biotherapeutics$ARWR Arrowhead Pharmaceuticals$ATTO Attovia Therapeutics$ATYR aTyr Pharma$AUPH Aurinia Pharmaceuticals$AUTL Autolus Therapeutics$AVTX Avalo Therapeutics$AVXL Anavex Life Sciences$AXSM Axsome Therapeutics$BBIO BridgeBio Pharma$BBOT BridgeBio Oncology Therapeutics$BCDA BioCardia$BCRX BioCryst Pharmaceuticals$BCTX BriaCell Therapeutics$BDRX Biodexa Pharmaceuticals$BEAM Beam Therapeutics$BFRI Biofrontera Inc.$BHVN Biohaven$BLLN BillionToOne$BLSM BlossomHill Therapeutics$BLTE Belite Bio$BMEA Biomea Fusion$BTSG BrightSpring Health Services$CADL Candel Therapeutics$CANF Can-Fite BioPharma$CAPR Capricor Therapeutics$CBIO Crescent Biopharma$CELC Celcuity$CERT Certara$CGEM Cullinan Therapeutics$CGTX Cognition Therapeutics$CING Cingulate Inc.$CLDX Celldex Therapeutics$CLGN CollPlant Biotechnologies$CLYM Climb Bio$CMPS Compass Pathways$CMPX Compass Therapeutics$CODX Co-Diagnostics$COGT Cogent Biosciences$CORT Corcept Therapeutics$CRBP Corbus Pharmaceuticals$CRDF Cardiff Oncology$CRDL Cardiol Therapeutics$CRMD CorMedix$CRSP CRISPR Therapeutics$CTNM Contineum Therapeutics, Inc.$CYTK Cytokinetics$DCOY Decoy Therapeutics$DFTX Definium Therapeutics$DMAC DiaMedica Therapeutics$DNTH Dianthus Therapeutics$DRMA Dermata Therapeutics$DRTS Alpha Tau Medical$DYN Dyne Therapeutics$EDSA Edesa Biotech$ELTX Elicio Therapeutics$EPRX Eupraxia Pharmaceuticals$ETON Eton Pharmaceuticals$EWTX Edgewise Therapeutics$EYPT EyePoint Pharmaceuticals$FATE Fate Therapeutics$FBIO Fortress Biotech$FDMT 4D Molecular Therapeutics$FULC Fulcrum Therapeutics$GERN Geron Corporation$GMAB Genmab A/S$GPCR Structure Therapeutics$GRAL GRAIL, Inc.$GUTS Fractyl Health$HELP Helus Pharma$HIMS Hims & Hers Health$HUMA Humacyte$IBIO iBio, Inc.$IBRX ImmunityBio$ICU SeaStar Medical$IDYA IDEAYA Biosciences$IMRX Immuneering Corporation$IMUX Immunic$IMVT Immunovant$INCY Incyte$INDV Indivior$INO INOVIO Pharmaceuticals$IONS Ionis Pharmaceuticals$IOVA Iovance Biotherapeutics$IRD Opus Genetics$IRON Disc Medicine$IVA Inventiva$KNSA Kiniksa Pharmaceuticals$KOD Kodiak Sciences$KPTI Karyopharm Therapeutics$KRRO Korro Bio$KYMR Kymera Therapeutics$LBRX LB Pharmaceuticals$LEGN Legend Biotech$LFWD Lifeward$LGVN Longeveron$LPCN Lipocine$LRMR Larimar Therapeutics$LXRX Lexicon Pharmaceuticals$MANE Veradermics$MBOT Microbot Medical$MBRX Moleculin Biotech$MDAI Spectral AI$MDGL Madrigal Pharmaceuticals$MEDP Medpace$MEDS DataMeds AI$MIST Milestone Pharmaceuticals Inc.$MLYS Mineralys Therapeutics$MNDR Mobile-health Network Solutions$MNKD MannKind Corporation$MRNA Moderna$MSLE Satellos Bioscience$MTVA MetaVia$MYGN Myriad Genetics, Inc.$NAUT Nautilus Biotechnology$NKTR Nektar Therapeutics$NNVC NanoViricides, Inc.$NRXP NRx Pharmaceuticals$NTLA Intellia Therapeutics$NVAX Novavax$NVCR Novocure$NVO Novo Nordisk$NYXH Nyxoah$OCGN Ocugen$OCS Oculis Holding AG$OCUL Ocular Therapeutix$OGN Organon$OMER Omeros Corporation$ONCY Oncolytics Biotech$ORIC ORIC Pharmaceuticals$ORKA Oruka Therapeutics$OSCR Oscar Health$OTLK Outlook Therapeutics$PACB Pacific Biosciences of California, Inc.$PCVX Vaxcyte$PDSB PDS Biotechnology$PGEN Precigen$PHVS Pharvaris$PLX Protalix BioTherapeutics$PMVP PMV Pharmaceuticals$PRAX Praxis Precision Medicines$PRME Prime Medicine$PROK ProKidney$PTGX Protagonist Therapeutics, Inc.$PYPD PolyPid Ltd.$QNTM Quantum BioPharma$QTTB Q32 Bio$QURE uniQure$RAPP Rapport Therapeutics$RARE Ultragenyx Pharmaceutical$RCKT Rocket Pharmaceuticals$REPL Replimune Group$RGNX REGENXBIO$RIGL Rigel Pharmaceuticals$RLAY Relay Therapeutics$RNXT RenovoRx$RXRX Recursion Pharmaceuticals, Inc.$RZLT Rezolute$SANA Sana Biotechnology$SCTX Scribe Therapeutics$SCYX SCYNEXIS$SENS Senseonics Holdings$SGMT Sagimet Biosciences$SLN Silence Therapeutics$SLS SELLAS Life Sciences$SMMT Summit Therapeutics$SNDX Syndax Pharmaceuticals$SPRO Spero Therapeutics$SRPT Sarepta Therapeutics$SRRK Scholar Rock$STIM Neuronetics$STOK Stoke Therapeutics$SVRA Savara$SYRE Spyre Therapeutics$TAK Takeda Pharmaceutical Company Limited$TARA Protara Therapeutics$TENX Tenax Therapeutics$TGTX TG Therapeutics$TLX Telix Pharmaceuticals$TNGX Tango Therapeutics$TRAW Traws Pharma$TRAX First Tracks Biotherapeutics$TRDA Entrada Therapeutics$TVTX Travere Therapeutics$TYRA Tyra Biosciences$UNCY Unicycive Therapeutics$URGN UroGen Pharma$VCRE Vicore Pharma$VERA Vera Therapeutics$VIR Vir Biotechnology$VKTX Viking Therapeutics$VNDA Vanda Pharmaceuticals$VOR Vor Biopharma Inc.$VRCA Verrica Pharmaceuticals$VRDN Viridian Therapeutics$VRTX Vertex Pharmaceuticals$VSTM Verastem Oncology$VTGN Vistagen Therapeutics$VTRS Viatris$VTVT vTv Therapeutics$WORX SCWorx Corp.$XBIO Xenetic Biosciences$XENE Xenon Pharmaceuticals$XERS Xeris Biopharma$XRTX XORTX Therapeutics$ZBIO Zenas BioPharma$ZLAB Zai Lab$ZNTL Zentalis Pharmaceuticals$ZURA Zura Bio$ZVRA Zevra Therapeutics$ZYME Zymeworks

Why this hub exists

Biotech is one of the few equity sectors where a single company update can completely change the market narrative in one session. A trial readout, an FDA decision, a safety signal, a financing, a regulatory delay, a partnership, or even a conference abstract can move a stock far more than ordinary quarterly numbers.

This hub is designed as a clean starting point for readers who want to follow biotech stocks with a catalyst-first mindset. The goal is not to chase every press release, but to organize the sector around what actually matters for traders: clinical-stage risk, cash runway, dilution pressure, regulatory milestones, institutional positioning, insider behavior, market sentiment, and the difference between a real inflection point and a temporary headline spike.

Core focusEvent-driven biotech
Main risksData, FDA, cash
Reader useResearch map
StyleEducational only

How to read a biotech setup

A biotech stock is rarely just a chart. The chart matters, but the real driver is usually a chain of questions: what asset is being developed, what disease is being targeted, what stage the program is in, how strong the prior data looked, how much cash the company has, how soon the next milestone arrives, and how the market is currently pricing the probability of success.

1. The asset

Start with the drug, device, platform or therapy. What is it supposed to do, what pathway does it target, and why could it matter clinically?

2. The indication

A rare disease, oncology, neurology or cardiometabolic program can carry very different timelines, endpoints, competitive intensity and regulatory paths.

3. The catalyst

Identify the actual event: topline data, PDUFA, advisory committee, abstract, conference presentation, trial initiation, enrollment completion or regulatory filing.

4. The balance sheet

Cash runway and dilution risk matter. Positive data can be powerful, but weak financing conditions can cap the upside or trigger a capital raise.

Biotech categories we track

The hub organizes Merlintrader biotech coverage by catalyst type and clinical theme. This keeps the reader from treating every ticker as the same kind of trade.

FDA / PDUFA names

Companies approaching FDA action dates, regulatory submissions, label decisions, complete response letter recovery paths or advisory committee events.

PDUFAFDAAdCom

Clinical readout names

Small and mid-cap stocks with pending Phase 1, Phase 2 or Phase 3 data where efficacy, safety or durability can reset valuation.

Phase 1Phase 2Phase 3

Commercial launch stories

Biotechs moving from approval to execution, where prescriptions, payer coverage, physician adoption and guidance become the main story.

LaunchRevenueGuidance

Platform stories

Gene editing, RNA, cell therapy, radiopharma, immunology and next-generation modalities where one program may validate a broader technology stack.

PlatformPipelineValidation

Research checklist for any biotech catalyst

This is the practical filter used across Merlintrader biotech coverage. A stock can look exciting on social media, but sound research separates the real catalyst from the noise.

01

Confirm the exact catalyst

Vague phrases like “data soon” say little. A useful catalyst entry identifies the type of event, expected window, trial name, indication and whether the timing is company-guided or only market speculation.

02

Read the trial design

Endpoints, population size, control arm, follow-up duration and prior data quality matter more than the headline alone.

03

Check cash and dilution

A biotech with a short runway may use strength to raise capital. That does not automatically kill a thesis, but it must be part of the setup.

04

Map institutional and insider behavior

Ownership changes, insider buying or selling, and recent financings help frame market confidence, but they should not replace clinical analysis.

05

Separate upside scenario from probability

A huge addressable market does not equal a high-probability trade. The question is what the market already discounts and what new evidence can change.

More Merlintrader biotech research

Use these links to move from this sector hub into deeper research, live catalyst tracking and related educational material.

What makes biotech different from ordinary stock research

Biotech research is not simply a question of revenue, margins and guidance. Many companies in this sector have no commercial revenue at all, or only limited early revenue, while the market value is built around future medical, regulatory and strategic possibilities. That makes the sector fascinating, but also dangerous. A company can look expensive on traditional financial metrics and still be underpriced if a late-stage asset works. Another company can look statistically cheap and still be a value trap if its lead program fails, if the FDA asks for another trial, or if the balance sheet forces a painful financing.

The best way to approach biotech is to think in layers. The first layer is the science: mechanism of action, disease biology, endpoint relevance, prior clinical evidence and safety profile. The second layer is the regulatory path: FDA division, trial design, accelerated approval possibility, advisory committee risk, labeling questions and post-approval commitments. The third layer is the market structure: competing therapies, standard of care, physician behavior, reimbursement, pricing and commercial execution. The final layer is the stock itself: liquidity, float, short interest, institutional sponsorship, insider behavior, retail attention and how much of the story is already priced in.

This hub is built around that layered approach. The purpose is to help readers slow down, organize the facts and avoid treating every biotech headline as if it had the same quality. A Phase 1 safety update is not the same as a Phase 3 primary endpoint readout. A conference abstract is not the same as a peer-reviewed publication. A granted patent is not the same as regulatory approval. A partnership discussion is not the same as a funded collaboration. Those distinctions are often where traders either protect themselves or get trapped.

The main biotech catalyst types

Not all catalysts deserve the same weight. Some events can reset valuation immediately; others are useful but mostly confirm that a program is still moving forward. A serious biotech watchlist should rank catalysts by potential market impact, probability, timing clarity and downside risk if the event disappoints.

Topline clinical data

This is usually the most important catalyst for development-stage companies. The market focuses on whether the trial met its primary endpoint, how secondary endpoints behaved, whether safety was clean, and whether the data are strong enough to support the next regulatory or commercial step.

FDA approval decisions

PDUFA dates can create large moves because they convert a development story into a regulatory decision. The key questions are approval, rejection, label breadth, safety warnings, manufacturing issues and whether launch can begin quickly.

Advisory committee events

An AdCom can be a major swing event because outside experts discuss efficacy, safety and risk-benefit in public. The vote matters, but the tone of discussion can matter just as much.

Conference abstracts and presentations

Medical congresses can bring fresh data, longer follow-up, subgroup analysis or competitive context. The market often reacts before the full presentation, especially when abstracts are released ahead of the event.

Financing and strategic transactions

A capital raise, royalty deal, licensing agreement or partnership can extend runway and validate a program, but terms matter. Dilution can be acceptable when it funds a strong catalyst; it can be destructive when it only buys time.

Commercial launch updates

For approved products, the story shifts from clinical risk to execution risk. Prescription trends, payer coverage, inventory dynamics, gross-to-net, sales force productivity and guidance become central.

How Merlintrader separates real biotech momentum from noise

Momentum in biotech can be real, but it can also be manufactured by thin liquidity, social media excitement or recycled headlines. A stock moving sharply does not automatically mean that the fundamental probability has improved. The first question is always: what changed today compared with what the market knew yesterday?

A strong setup normally has at least one of three elements. First, a new and verifiable piece of information: clinical data, regulatory feedback, financing, partnership, publication, trial update or official guidance. Second, a clear calendar reason for attention: an upcoming FDA date, conference presentation, data window or earnings call that can clarify launch execution. Third, an imbalance between attention and information: the market may be discovering a catalyst late, especially in small caps with limited institutional coverage.

A weak setup often looks exciting at first but fails under basic checks. The catalyst is vague. The company has very little cash. The trial is early and uncontrolled. The endpoint is exploratory. The same news was already announced months earlier. Management language is promotional but not precise. The move is driven by message-board speculation rather than a filing or official source. In those cases, the correct job of research is not to kill the story automatically, but to mark the difference between fact, interpretation and hype.

Featured biotech research areas for this hub

The biotech universe is too large to treat as one bucket. Merlintrader coverage will prioritize names where the catalyst is visible, the market reaction can be meaningful, and the story can be explained clearly to readers. The focus is not only on the biggest companies. Small and mid-cap biotech often produces the most asymmetric moves, but it also demands stricter risk control.

FDA

Regulatory decision stocks

Companies approaching PDUFA dates, FDA resubmissions, label expansion decisions, advisory committees or complete response letter recovery attempts. These names require a precise review of prior data, regulatory history, manufacturing risk and label expectations.

DATA

Clinical readout stocks

Companies with upcoming Phase 1, Phase 2 or Phase 3 data. A complete assessment covers trial design, patient population, endpoint hierarchy, statistical powering, prior studies, safety signals and what would count as a clearly positive or clearly negative result.

RARE

Rare disease companies

Rare disease biotech can move strongly because small patient populations may still support attractive economics, especially when disease burden is high and competition is limited. However, trial size, endpoint choice and regulatory flexibility must be examined carefully.

ONC

Oncology and hematology

Oncology readouts often require more nuance than a headline response rate. Durability, complete responses, progression-free survival, overall survival, safety, line of therapy and competing datasets all matter.

CNS

Neurology and psychiatry

CNS programs can be extremely valuable but difficult to interpret. Placebo response, subjective endpoints, trial design, patient selection and safety tolerability often determine whether a headline result is truly investable.

COMM

Commercial-stage biotech

Once a drug is approved, the market wants evidence that physicians prescribe it, payers cover it, patients stay on therapy and management can scale revenue without destroying margins.

The Merlintrader RunUP Biotech strategy

Merlintrader approaches biotech not only as a sector of medical innovation, but also as one of the market’s most powerful event-driven trading arenas. The core idea behind RunUP Biotech is the phase in which attention, volume, speculation and institutional positioning can build before a known clinical or regulatory catalyst. This is not the same as betting blindly through binary data. In many cases, the more disciplined opportunity lies not in the event itself, but in the market behavior that develops before it.

A run-up begins when a catalyst becomes visible enough to attract attention, but not yet fully digested by the market. The best setups often combine a defined calendar window, a credible scientific or regulatory reason for interest, a stock that has not already priced perfection, and improving market awareness. The move can be driven by anticipation rather than confirmation. That is why the work begins before the headline, not after it.

The Merlintrader approach is built around one simple principle: respect the catalyst, but do not worship it. A catalyst can create opportunity, but it can also destroy capital. The purpose of the run-up strategy is to identify when the market is starting to care, understand why it is starting to care, and evaluate whether the risk/reward still makes sense before the binary moment arrives.

We track the calendar

FDA dates, clinical data windows, congress presentations, earnings calls, trial completion dates and regulatory submissions create the structure of the trade. Without timing, there is no run-up map.

We study the story

The catalyst must have a reason to matter. A stock can have a date on the calendar, but if the asset is weak, the trial is unclear or the market opportunity is limited, the run-up may be fragile.

We watch the tape

Volume expansion, higher lows, improving liquidity, better news response and stronger sector context can confirm that attention is building. A catalyst with no tape support may stay invisible.

We manage the binary risk

The event itself can be dangerous. Holding through data or FDA decisions is a separate decision from trading the anticipation phase. That distinction is central to the Merlintrader style.

Run-up does not mean “buy before news and hope”

A proper biotech run-up strategy is not hype. It is not a social media chase. It is not buying a ticker simply because someone says “data soon.” A real run-up framework starts with evidence and ends with risk control. The question is not whether a company sounds exciting. The question is whether the market has a reason to reprice the stock before the catalyst, and whether the current price still leaves room for that repricing.

The cleanest run-up setups usually have several pieces working together. First, there is a known or strongly guided catalyst window. Second, the program has enough prior evidence to make investor attention rational. Third, the stock has not already completed the entire move. Fourth, the balance sheet is not so weak that every rally becomes an immediate financing opportunity. Fifth, the broader biotech tape is not completely hostile. None of these factors guarantees success, but together they create a better research foundation.

The weakest setups are the opposite. The catalyst is vague, the source is not official, the company needs cash immediately, prior data are thin, the stock has already exploded, and traders are mostly repeating each other. Those can still move, but they do not deserve confident language. They are speculative, fragile and high-risk.

The phases of a biotech run-up

One of the biggest mistakes in biotech trading is treating the whole move as one event. In reality, a run-up often develops in phases. Understanding the phase helps the reader judge how mature a move is and avoid mistaking exhaustion for early momentum.

1

Discovery phase

The catalyst exists, but only a small part of the market is paying attention. Volume is still normal or only slightly above normal. This phase is research-heavy because the edge comes from understanding the calendar before it becomes obvious.

2

Awareness phase

The stock starts appearing on watchlists. Volume improves, social attention rises, and the story begins to circulate. Good reports can help readers understand whether the attention is justified or just noise.

3

Acceleration phase

The market starts pricing the catalyst more aggressively. This is often the fastest part of the move, but also where risk increases quickly because late buyers often enter without understanding the underlying event.

4

Decision phase

The trader must decide whether the run-up trade is over, whether partial de-risking makes sense, or whether holding through the binary event is justified. This is a risk decision, not an emotional decision.

5

Aftermath phase

After data or FDA action, the story changes. A successful catalyst becomes a new valuation exercise. A failed catalyst becomes a damage-control exercise. Either way, the run-up phase is finished.

What readers should take away

The objective is not to turn readers into blind biotech gamblers. The objective is to teach them how to read the setup. A good reader should leave Merlintrader understanding what the catalyst is, why it matters, what can go right, what can go wrong, where the uncertainty sits, and why the stock is moving now.

That is why useful biotech coverage goes beyond a standard market note. A one-line headline can tell readers that a company has data coming. It cannot explain the disease, the endpoint, the prior evidence, the financing risk, the competitive landscape, the retail narrative, institutional ownership, the insider record, the scenario tree or the difference between trading the run-up and holding through the event. That deeper context is where Merlintrader can be useful.

Understand the catalyst

A catalyst should be understandable to a non-specialist without being dumbed down.

Understand the timing

The reader should know whether the event is days away, weeks away, quarter-guided or still uncertain.

Understand the risk

No catalyst is free money. Biotech risk must be explained clearly and directly.

Understand the trade structure

The reader should understand the difference between anticipation, confirmation and binary-event exposure.

What can break a run-up

A run-up can fail even before the main catalyst arrives. This is why the failure modes deserve equal attention. The most common problem is dilution. If a company has limited cash and the stock rallies, management may raise money before the catalyst. Sometimes that is rational and even necessary, but it can still hurt traders who entered late. Another problem is timing slippage. A catalyst expected in one quarter may move into the next one, and momentum can fade quickly when the calendar becomes less urgent.

There is also the problem of overpricing. A stock that doubles or triples before data may leave very little room for disappointment. Even positive data can sell off if the market expected perfection. Competitive read-throughs can also hurt: a rival dataset, FDA comment, safety issue or commercial update can change the perceived value of a program before the company reports anything new.

The final risk is narrative exhaustion. In small-cap biotech, attention can be temporary. When volume dries up, the same story that looked powerful during the acceleration phase can suddenly feel abandoned. The quality of the science must therefore be separated from the quality of the trade setup. They are connected, but they are not identical.

What a Merlintrader biotech deep dive covers

Each Merlintrader biotech ticker page is designed so a reader can understand the full story without opening ten tabs. The analysis moves from simple to complex: first the company, then the asset, then the catalyst, then the financial and market context.

Executive summary

A plain-English overview of what the company does, why the stock matters now, what the next catalyst is and what the biggest risk is.

Company background

History, corporate strategy, pipeline, lead asset, therapeutic area, management profile and how the current story developed.

Clinical and regulatory review

Trial names, phases, endpoints, prior data, FDA interactions, expected timeline and what investors should watch in the next update.

Financial snapshot

Cash, debt, burn rate, runway, recent offerings, ATM facilities, warrants and the likelihood that the company may need capital.

Ownership and market behavior

Institutional holders, insider activity, short interest, float dynamics, volume changes and retail attention.

Scenario analysis

Bull, base and bear cases written clearly, without pretending that uncertain outcomes are guaranteed.

Important risk note

Biotech can move violently in both directions. Positive trial results can trigger large upside gaps, but failed endpoints, safety concerns, FDA delays, complete response letters, weak launches, dilution, debt pressure or strategic uncertainty can create severe losses. This hub is built for research and education, not for buy or sell recommendations.

Next biotech research stop

Start with the calendar, then move into the deep dives. The best biotech reports usually begin with the event window, then work backward into science, cash, valuation and market expectations.

Biotech Catalyst Calendar 2026

What a Merlintrader deep dive includes

  • Company story: what the company actually does.
  • Lead asset: mechanism, indication and clinical stage.
  • Catalyst map: exact milestone and expected timing.
  • Financial snapshot: cash, burn, runway and dilution risk.
  • Ownership: insiders, institutions and recent changes.
  • Scenarios: bull, base and bear case.

Get these reports in real time

Join the Merlintrader Telegram channel and receive every new deep dive and market update the moment it goes live.

Join @merlintraderpub_com on Telegram

Educational disclaimer. This page is for informational and educational purposes only and does not constitute financial advice, investment advice, medical advice, a solicitation, or a recommendation to buy or sell any security. Biotech equities are high-risk and can be extremely volatile around clinical, regulatory and financing events. Always conduct independent research and consult a qualified professional before making financial decisions.

Disclaimer. The reports in this library are published by Merlintrader for educational and informational purposes only. They are independent journalism and research, dated to the day printed on each report. They do not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and they are not research reports within the meaning of applicable United States securities regulation.

Figures come from public filings, company releases, official trial registries and regulatory documents, stated with their reference dates. They become outdated as new filings and events occur: verify every figure against the primary source and the current stock hub before relying on it. Small and mid-cap and biotechnology stocks can be extremely volatile and may result in partial or total loss of capital. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Reports are for personal use only. Redistribution is prohibited. Full legal information is available on the disclaimer and terms of use and privacy pages.